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ABSTRACT 
Marni B. Siegel: Genetic Drivers and Clonal Heterogeneity of Metastatic Breast Cancer 
(Under the direction Charles M. Perou and Carey K. Anders) 
 
Breast cancer remains the second leading cause of cancer related death in women in 
the United States. Despite great advances in both early detection and treatment for primary 
breast cancer, 40,000 women die of breast cancer each year. Metastasis, namely when cancer 
spreads beyond the original site, is the main cause of breast cancer mortality. A lack of 
understanding of metastasis continues to thwart prevention and treatment of lethal breast 
cancer. Genome-wide comparisons of both the genetic composition (DNA) and expression 
(RNA) of primaries and metastases in multiple patients could help elucidate the underlying 
mechanisms causing breast cancer metastasis. 
In this thesis, next-generation sequencing was performed on a dataset of patients with 
both primary breast cancers and multiple distant metastases. DNA and RNA sequencing were 
performed on 16 breast cancer patients with 86 matched tumors (primary + multiple 
metastases). We confirmed previous work that the primary cancer is extremely diverse with 
multiple distinct populations of cells. Comparisons of these populations in the original tumor and 
the distant metastases demonstrates that in some instances, it is likely that a clump of cells 
containing multiple different genetic populations together leave the breast and seed distant 
sites. Finally, a novel computational method integrating RNA gene expression, somatic copy 
number alterations, and somatic mutations identifies drivers of breast cancer in matched 
primaries, metastases, and in the broader context of breast cancer as a whole. We show that a 
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majority of the drivers of breast cancer are established in the original cancer and maintained in 
metastasis. 
This work asks clinically impactful questions of the biology of breast cancer metastasis 
through multiple genomic approaches. The body of knowledge presented here demonstrates 
that the complex heterogeneity in primary breast cancer is maintained throughout metastasis 
while also proving that the majority of genetic drivers in metastasis are established in the 
original breast cancer. Finally, we demonstrate that common mechanisms driving breast cancer 
are utilized across the previously-described molecular and clinical subgroups of breast cancer, 
offering novel, tractable therapeutic targets. These findings contribute significantly to our 
understanding of the genetic diversity and drivers of lethal breast cancer metastasis. 
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CHAPTER 1 – INTRODUCTION 
Breast cancer is the second leading cause of cancer-related death in women, 
accounting for 40,000 deaths each year in the United States. Progression to metastasis is the 
predominant cause of breast cancer mortality. Brain metastases represent a particularly dire 
consequence of advanced breast cancer with no approved systemic therapeutics and limited 
survival. Understanding the underlying biology driving the metastatic phenotype (i.e. molecular 
drivers of seeding, invasion, and growth at a distant site) could provide novel therapeutic targets 
to prevent and treat metastatic breast cancer.  
 
Breast Cancer Heterogeneity 
Breast cancer is not a single disease but rather a collection of diseases having unique 
morphologies, gene expression profiles, DNA mutation profiles, DNA copy number alterations, 
widely varying clinical responses, differences in hormone receptor expression, and variations in 
patterns of metastasis. Systemic treatment of breast cancer begins with identifying hormone 
receptor positivity based on the estrogen receptor (ER), progesterone receptor (PR), and 
epidermal growth factor receptor 2 (HER2) expression coming from tumor cells. RNA gene 
expression studies define four dominant subgroups of breast cancer: Luminal A, Luminal B, 
HER2-enriched, and Basal-like breast cancer (Perou et al., 2000). Luminal A breast cancers are 
typically ER positive and have lower proliferation rates than the Luminal B tumors. Luminal B 
tumors have poorer overall survival and tend to relapse predominantly in the bone. HER2E 
tumors have increased expression of the HER2 DNA amplicon genes. Finally, the basal-like 
breast cancers are the most poorly differentiated and typically lack expression of ER, PR, and 
 
 
2 
HER2.  Patients with basal-like tumors represent the greatest clinic need, with a paucity of 
targeted therapies clinically available and the worst 5-year overall survival.  
Breast cancer subtype captures some of the clinical heterogeneity including first site of 
metastasis. Luminal tumors often first metastasize to the bone, HER2E tumors to the liver, and 
basal-like tumors to the lung and brain. Furthermore, the timeline for recurrence is dramatically 
different: basal-likes typically recur within three years following diagnosis but highly unlikely to be 
past 5 years, while the hormone-positive tumors often may not recur until closer to 10 years after 
diagnosis. This has been shown to be a result of both treatment differences and the underlying 
biology. 
There is substantial heterogeneity even within the subtypes of breast cancer. Luminal A 
breast cancers can have highly variable responses to current therapies. Molecular studies of the 
copy number landscape of luminal breast cancers have further shown 5 subtypes of these 
tumors: a copy number neutral subgroup which lack TP53 mutation and have the best prognosis, 
three intermediate groups, and one highly copy number altered subgroup which harbor TP53 
mutations and have the worst overall prognosis (Ciriello et al., 2013). These two extremes are 
also reflected in the METABRIC cohort, which defined subgroups of breast cancer based on 
copy number and gene expression (Curtis et al., 2012). RNA gene expression of these luminal 
tumors further defined drivers of the tumors with increased proliferation rates, including MYC 
amplification and RB loss (Gatza et al., 2014).  
Not only is there substantial DNA alteration heterogeneity within subtypes of breast 
cancer, but there is also differences in the stromal response to these tumors. Immune infiltrate 
has been shown to have prognostic value in the HER2E and Basal-like breast cancer subtypes, 
indicating that variability across this subtype is present (Iglesia et al., 2014). Additionally, 
cancer-cell associated fibroblasts behave differently around basal-like breast cancers in 
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comparison to luminal breast cancers (Camp et al., 2011). Finally, a distinct host-wound 
response varies by subtype (Troester et al., 2009), with increased hypoxia and altered 
metabolic program around basal-like breast cancers (Harrell et al., 2012). 
Unfortunately, this heterogeneity extends even within a single patient’s tumor. An 
elegant study of multiregional sequencing of breast cancer demonstrated that primary breast 
cancers have spatial heterogeneity (Yates et al., 2015). In almost all patients, mutations were 
observed in one part of the tumor but not another. Thus, there were multiple populations of 
cancer cells within a single tumor. Heterogeneity by point mutation was shown in 9/12 patients. 
This is contrast to heterogeneity measured by copy number alteration, which was shown only in 
3/12 patients.  
 
Monoclonal vs Polyclonal Seeding of Metastasis 
It is currently unknown what portion of the heterogeneity elucidated from Yates et al. 
leaves the original breast cancer and causes distant metastasis. Two possibilities may occur: 
monoclonal vs polyclonal seeding of metastasis. In the first instance, a single cell may escape 
the original tumor, representing one distinct population of cells from the original breast cancer, 
that then seeds a distant site. In contrast, possibly a chunk of the primary breast cancer moves 
into the circulation and together seeds a distant site. Thus, the distant site of metastasis would 
reflect the heterogeneity measured in the original breast cancer. 
To better understand the process of clonal evolution in metastasis, many groups have 
studied matched primaries and single sites of metastasis. The seminal work in renal cell 
carcinoma hypothesized that metastasis is a result of a single clone escaping the primary cancer 
followed by clonal expansion (Gerlinger et al., 2012). Few mutations from the primary were 
observed in the distant metastasis. Recently, multi-metastatic sequencing compared prostate 
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cancer metastases to the matched primary, demonstrating both mechanisms of seeding 
(Gundem et al., 2015). The authors hypothesize metastasis-to-metastasis seeding in which a 
chunk of tumor from one metastasis breaks off and seeds another site. 
In an ovarian cancer study, multiple primary tumors were compared to later time points 
following recurrence (Castellarin et al., 2013). Their results demonstrate multiple clones in the 
primary that are maintained through metastasis, indicating polyclonal seeding of metastasis. This 
in contrast to AML in which clonal expansion of a therapy-resistant clone was observed following 
treatment (Ding et al., 2012). 
In breast cancer, Nik-Zainal and colleagues published whole genome sequencing of 21 
breast cancers and later 560 whole genome sequences of breast cancers (Nik-Zainal et al., 
2016). Sequencing of a matched basal-like breast cancer normal, primary, metastasis, and 
xenograft demonstrated that all of the original mutations were maintained in metastasis to the 
brain with continued evolution in the brain metastasis (Ding et al., 2010). In addition, the overall 
copy number structure was extremely similar to the original tumor (Ding et al., 2010). In array 
CGH comparisons of 23 primary breast cancers and matched metastases, copy number was 
shown to be highly concordant – 92% for recurrent variants and 73% for non-recurrent variants.  
22/23 patients would have similar targeted therapy based on sequencing, further providing 
evidence of the genetic similarity of primary and metastatic disease (Bertucci et al., 2014). 
Whole exome sequencing of matched normal tissue, ductal carcinoma in situ(DCIS), a 
primary tumor, and a loco-regional lymph node metastasis demonstrate linear progression and 
monoclonal seeding (Krøigård et al., 2015). Importantly, genetic alterations were stable: if the 
alteration was observed in the primary, it was also observed in the metastasis. The complete 
events maintained in the primary and observed in the metastasis argue for a single cell to be the 
ancestor with a relatively late occurrence of metastasis in this patient. 
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Single cell sequencing of breast cancer found single clonal expansion from the primary to 
the liver metastasis as shown in mutations; however, they also showed that a very similar copy 
number profile was observed in all cells sequenced (Navin et al., 2011). This was done in only 
one patient and only one site of metastasis. Sequencing of matched brain metastases and 
primary breast cancers argued that clinically actionable mutations were acquired during spread 
of disease and not previously observed in the primary tumor (Brastianos et al., 2015).  
DNA from cancer cells identified in the blood offer another glimpse into the clonal 
evolutionary process of breast cancer. In a study of two patients with metastatic breast cancer, 
whole exome sequencing of both the tumor and cell free DNA were compared (Butler et al., 
2015). Both ESR1 mutations and PIK3CA mutations were identified in the metastatic and primary 
tumors, respectively, but not observed in the others. Authors showed that the cell free DNA 
(cfDNA) more closely reflects the metastases rather than the primary tumor.  
Three elegant in vivo study of the actual physiologic process of breast cancer metastasis 
demonstrate how polyclonal seeding is physically possible. Circulating tumor cell clusters in vivo 
demonstrated that clusters of CTCs have much greater metastatic potential than single CTCs, 
although both were observed (Aceto et al., 2014). A combined red and green fluorescent 
transgenic mouse breast cancer was injected into the mammary fat pad of mice and then 
analyzed lung metastases (Cheung et al., 2016). Cheung and colleagues demonstrate that 
metastases were between 2 to >1000 cells and all composed of at least red and green tumor 
cells. They further demonstrate that the extravasation process itself is a bulk tumor process 
(Cheung et al., 2016). Au and colleagues utilized microfluidic devices that mimic human capillary 
to study the fluid dynamics and extravasation of tumor cells (Au et al., 2016). Tumor cells were 
observed to squeeze through as small as 5 um spaces in single file before rounding up once 
through the passage and continuing their progress.  
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Timing of Metastatic Drivers  
RNA gene expression of a metastasis is 82% identical to the primary breast cancer from 
which it originated (Harrell et al., 2012; Hoadley et al., 2016), and subtype is generally 
maintained throughout the metastatic process (Weigelt et al., 2003). This provides evidence that 
the metastatic potential is likely in the original, primary breast cancer. The underlying biology 
responsible for successful metastatic seeding and growth are likely present in the primary 
breast cancer but remain unknown. Understanding genetic features driving metastasis, both in 
the primary breast cancer and in distant metastasis, could provide prognostic information as 
well as future, novel therapeutic targets. 
Prognostic signatures of metastasis based on genetic features in the primary breast 
cancer have been developed within our laboratory and independently by others as well. Clinical 
tools (i.e. PAM50 (Parker et al., 2009), Oncotype Dx (Paik et al., 2004), and MammaPrint (Glas 
et al., 2006)) stratify patients into high versus low risk of recurrence and are routinely employed 
in the clinic (Cardoso et al., 2016). In order for these to be prognostic, there must be some 
amount of metastatic potential in the primary breast cancer. Further research with primary 
breast cancers and multiple matched sites of metastasis are needed to elucidate the genetics 
causing these metastases. 
 
Metastasis-Specific Events 
Some genetic features specifically enriched in metastasis have been identified through 
RNA gene expression studies of small cohorts of human breast cancer metastases (Zhang et 
al., 2009). In human metastases, up-regulation of the hypoxia/VEGF signature (Hu et al., 2009) 
and down-regulation of extracellular matrix (ECM) signatures are differentially expressed in 
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metastasis as compared to primary breast cancers, suggesting alteration in the VEGF pathway 
and remodeling of the ECM must occur for successful metastasis. Organ-specific drivers of 
breast cancer metastasis were identified in in vivo mouse models of lung, bone, and brain 
metastases (Bos et al., 2009; Minn et al., 2005; Sevenich et al., 2014; Valiente et al., 2014; 
Zhang et al., 2009). In these preclinical studies, overexpression of SRC and COX2 are critical 
for bone metastasis, MTDH is sufficient for lung metastasis, and neuroserpin expression is 
necessary for brain metastasis. The specific DNA alterations that drive these gene expression 
changes in metastases, and the order in which they occur, remain unknown. Moreover, 
reproducibility in the human condition has yet to be described.  
While some genetic drivers of metastasis are inherent to tumor cells themselves, the 
tumor microenvironment also plays a vital role in successful tumor cell seeding and survival 
(Fidler, 2001). Recent literature suggests that some primary breast cancer cells already express 
proteins essential for the establishment of breast cancer brain metastases (BCBMs), including 
serpins (Valiente et al., 2014), cathepsin S (Sevenich et al., 2014), matrix metalloproteases 
(Romagnoli et al., 2014; Wang et al., 2013), and αB-crystallin (Malin et al., 2014). Once in the 
brain, BCBMs up-regulate proteins to enable transport and metabolism of GABA, increasing 
tumor cell proliferation (Neman et al., 2014). Targeting reactive astrocytes in the tumor 
microenvironment with drugs decreases brain seeding and growth in vivo (Gril et al., 2013), 
signifying a reliance of BCBMs on the brain microenvironment. Identification of key drivers of 
breast cancer metastases, both within the tumor and its surrounding microenvironment, will be 
critical to acquire a comprehensive understanding metastatic biology. 
Breast cancer brain metastases have an extremely poor survival with median survival 
from CNS recurrence at 4.9 months. Within the triple negative breast cancer classification, 46% 
of patients with metastases will develop brain recurrence and subsequently have a median 
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survival of 13.3 months following CNS recurrence (Lin et al., 2008). We must put our resources 
towards understanding the biology of this lethal form of breast cancer in order to develop a cure 
and save lives. 
 
Genetic Drivers of Breast Cancer  
Large-scale sequencing efforts have afforded the opportunity to identify recurrent 
mutations and copy number alterations. Uncovering the incredible genetic diversity within breast 
cancer, The Cancer Genome Atlas (TCGA) demonstrated very few recurrent mutations in the 
most aggressive form of breast cancer, basal-like breast cancer, other than TP53 (Cancer 
Genome Atlas, 2012). A recent study of 560 breast cancers with whole genome sequencing 
identified very few recurrent drivers other than those previously described (Nik-Zainal et al., 
2016). Interestingly, in ER+ breast cancer, the mutation burden is often much lower; however, 
there are more recurrently mutated genes in ER+ positive breast cancer including PIK3CA, 
GATA3, and FOXA1. With the decreasing cost of high-throughput sequencing, the ability to 
integrate multiple platforms of genetic data provides a unique opportunity to better identify 
genetic drivers. Computational predictions of the impact of a mutation on the cancer cell 
development, growth, and metastatic potential typically incorporate both the location of the 
mutation on the protein and the number of mutations in a dataset (Dees et al., 2012b; Lawrence 
et al., 2013). 
Breast cancer is a highly copy number altered disease; however, the large spans of 
genomic space altered makes identifying the actual driver(s) difficult. Several computational 
approaches have been previously described to narrow the candidate drivers.  
Gatza and colleagues integrated a small interfering RNA screen, with gene expression-
based pathway signatures, and copy number data (Gatza et al., 2014). By comparing the most 
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proliferative ER+ luminal A breast cancers to those with lower proliferation scores, MYC and RB 
were identified as the most likely candidates driving this proliferative phenotype (Gatza et al., 
2014). Silva and colleagues took a different approach by comparing cross-species conserved 
regions of basal-like breast cancer (Silva et al., 2015). Comparing known mouse models that 
faithfully recapitulate human breast cancer and integrating copy number analyses, RNA gene 
expression, and DawnRank driver analysis, they identified that NCSTN and IKBKE are critical 
drivers amplified at the 1q amplicon in basal-like breast cancer (Silva et al., 2015). Finally, 
integration of known protein-protein interaction networks, RNA gene expression, and DNA 
alterations allows for ranked candidate drivers (Hou and Ma, 2014). 
 
Tumor Microenvironment in Primary and Metastatic Breast Cancer 
Breast cancers develop in a milieu of cell types including epithelial fibroblasts, immune 
cells, and organ-specific cell types at the final sites of metastasis. Previous publications both by 
our group and others have demonstrated faithful measurement of tumor-infiltrating immune cells 
from both microarray data and RNA sequencing (Bindea et al., 2013; Iglesia et al., 2014). 
Increased immune infiltrate in basal-like and HER2-enriched breast cancer are known to be 
positively prognostic (Iglesia et al., 2014). Immune infiltrate also predicts response to 
immunotherapy in melanoma (Daud et al., 2016).  
In addition to bulk tumor-infiltrated immune cell measurements from gene expression 
data, novel computational methods can rebuild both the adaptive T cell receptor (Nazarov et al., 
2015), the B cell receptor repertoires (Mose et al., 2016), and predict neoantigens (Kardos et 
al., 2016). By integrating both DNA sequencing mutation calls with RNA sequencing, expression 
of the adaptive immune receptors and neoantigens can be computationally determined. The 
bioinformatics capacity to have further insight into the interaction of the immune and tumor 
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interface provide new opportunities in cancer research. 
The role of the immune system and metastasis is not well understood. Recent research 
provided evidence of a down-regulation of macrophages, T, B, and NK cells in the ‘metastasis’ 
relative to the ‘parental’ cell lines in vivo, hypothesizing that metastases achieve an immune-
escape mechanism mediated by Wnt signaling (Malladi et al., 2016); however, these studies 
were performed only in an immune-comprised mouse model with one human patient-derived 
xenograft from breast cancer. Therefore, further rigorous research in both immune-competent 
mouse models and human tissues are needed to understand the interaction of metastasis and 
the immune system. 
Not only is it currently unknown what type and level of immune infiltrate exists in 
metastasis, but we also do not know if it varies in different organ sites. Certainly, immune 
surveillance in normal lung, liver, and brain vary widely, with the brain typically thought of as an 
immune privileged organ. As we move into an era of immune modulatory agents, it will be 
critical to better understand the role of the immune system in metastasis.  
 
Research Introduction 
 Research elucidating the underlying mechanisms of metastasis is a great clinical need. 
Through this thesis, we sought to address three critical questions: (1) is breast cancer 
metastasis a monoclonal or polyclonal event (Chapters 2 and 3); (2) when are the genetic 
drivers of metastasis established (Chapters 2 and 3); and (3) what are the genetic drivers of 
metastasis (Chapter 3). We then explore the heterogeneity of genetic drivers across breast 
cancer in Chapter 4. Through this research, we hope to contribute to the field’s continued effort 
to find therapeutic targets to prevent and treat breast cancer metastasis. 
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CHAPTER 2 – TUMOR EVOLUTION IN TWO PATIENTS WITH BASAL-LIKE BREAST 
CANCER: A RETROSPECTIVE GENOMICS STUDY OF MULTIPLE METASTASES1 
Preface 
This work was previously published in PLOS Medicine as a co-first-authorship effort 
among Dr. Katherine Hoadley, Krishna Kanchi, and myself. I aided in the analysis of the 
expression of mutations in the RNA, identifying the timing with which DNA mutations were 
established, and interpreted the clonality studies performed by Chris Miller. In addition, I 
completed the figures, supplemental material, the writing of the manuscript, and all revisions. 
RNA sequencing was performed at UNC by Dr. Xiaping He and initially analyzed by Dr. Joel 
Parker and Dr. Hoadley. The DNA sequencing, mapping, validation, and structural variation 
calls were performed at the Washington University of St. Louis McDonnell Genome Institute by 
Krishna Kachni, Chris Miller, Li Ding, Ryan Demeter, Robert Fulton, and Michael Wendl. Chris 
Miller led the clonality analyses. Dr. Lisa Carey, Dr. Chuck Perou, and Dr. Elaine Mardis 
conceived, funded, and oversaw the project.  
Introduction 
Breast cancer patients who die from their disease typically succumb to a metastatic 
rather than primary tumor. Metastasis is a complex process likely involving many potentially 
                                                
1 This chapter previously appeared as an article in PLOS Medicine. The original citation is as follows: 
Hoadley KA*, Siegel MB*, Kanchi KL*, Miller CA, Ding L, Zhao W, He X, Parker JS, Wendl MC, Fulton 
RS, Demeter RT, Wilson RK, Carey LA, Perou CM†, Mardis ER†. “Tumor Evolution in Two Patients with 
Basal-like Breast Cancer: A Retrospective Genomics Study of Multiple Metastases.” PLoS Medicine 13, 
no. 12 (January 2017): e1002174. 
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distinct mechanistic steps. Biologically similar tumors vary in their ability to seed distant 
metastatic sites. Indeed, different molecular intrinsic subtypes of breast cancer as determined 
by the PAM50 subtype classifier vary markedly in their preferred sites for metastasis (Harrell et 
al., 2012; Sihto et al., 2011; Smid et al., 2008). The luminal subtypes often metastasize to the 
bone, HER2-enriched tumors to the lung and liver, and basal-like and claudin-low tumors to the 
brain, lung, and liver (Harrell et al., 2012; Sihto et al., 2011). The metastatic process is often 
described as a slow and continuous process of tumor evolution and acquisition of traits such as 
increased genomic instability, motility, and the epithelial-to-mesenchymal transition. Recent 
work in renal, prostate, ovarian, and lung cancer has identified significant amounts of intratumor 
variability in the primary tumor, as well as identifying new driver mutations that arose in 
metastases (de Bruin et al., 2014; Gerlinger et al., 2012; Gundem et al., 2015; Schwarz et al., 
2015; Zhang et al., 2014). In several breast cancer analyses of targeted gene panel, there was 
considerable concordance of mutations observed between primary tumors and matched 
metastases (Brastianos et al., 2015; Cummings et al., 2014; Meric-Bernstam et al., 2014; 
Moelans et al., 2014). This finding, combined with our increasing understanding that a particular 
intrinsic subtype predicts the future site(s) of metastasis, suggests that in breast cancer at least 
some of the metastatic potential already exists within the primary tumor (Harrell et al., 2012; 
Meric-Bernstam et al., 2014; Sihto et al., 2011; Smid et al., 2008). To examine this further, we 
studied the genomic relationship between the primary tumors and multiple matched metastases 
of two patients with triple-negative breast cancer (TNBC), with both cases also of the basal-like 
breast cancer intrinsic subtype. 
A common means of studying intratumor heterogeneity is to sample multiple parts of the 
same tumor and then perform genetic or genomic assays on these different regions. A more 
extreme approach to intratumor heterogeneity is to study a primary tumor and its associated 
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metastases to determine the extent to which the metastatic tumor genome was derived from the 
primary tumor cells as opposed to being an independent tumor (de Bruin et al., 2014; Gundem 
et al., 2015; McCreery et al., 2015; Shain et al., 2015; Zhang et al., 2014). Whether metastases 
can develop from the primary tumor or require continued evolution and gain of additional 
mutations in order to metastasize remains unknown in basal-like breast cancers, and 
addressing this issue may have important implications for therapy. In order to study the genomic 
evolution of basal-like breast cancer, we performed DNA whole genome and mRNA sequencing 
on two patients with matched primary tumors and multiple distant metastases.  
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Methods 
Patient Consent and Tissue Processing 
Tumor tissue was obtained from metastatic breast cancer patients who consented to a 
rapid autopsy at the University of North Carolina prior to death. Patient consent for the autopsy 
was obtained in accordance with the UNC Office for Human Research Ethics (OHRE) and 
criteria established by the US Department of HHS, but was not IRB regulated. There was no 
prospective analysis plan for this study. Primary, metastatic, and adjacent normal tissues were 
taken within 6 h of death for all metastatic sites identified prior to death and at time of autopsy. 
Tissues were frozen in liquid nitrogen, and RNA and DNA were isolated from each tissue using 
Qiagen RNAeasy and DNAeasy kits, respectively, according to manufacturer protocol (Qiagen, 
Valencia, California).  
Sequencing Methods 
RNA was isolated with RNeasy Mini Kit (Qiagen), and sequencing libraries were 
prepared with Illumina TruSeq RNA Sample Prep Kit (CAT #RS-122-2001) with the polyA select 
protocol, except for the A7-Brain, which was first prepared using the Epicentre’s Ribo-Zero 
rRNA Removal kit (Cat #RZH11042) (Zhao et al., 2014). RNA-seq was mapped with MapSplice 
(Wang et al., 2010) and quantified with RSEM (Li and Dewey, 2011). Upper-quantile normalized 
counts, log2 transformed, were combined with the Cancer Genome Atlas (TCGA) breast RNA-
seq data (Ciriello et al., 2015). Samples were median centered and clustered using the human 
breast cancer intrinsic gene set list (Parker et al., 2009), in Cluster 3.0 (Hoon et al., 2004) and 
visualized with Java TreeView v. 1.1.6r4 (Saldanha, 2004). 
 A previously described procedure was followed for library construction and sequencing 
(Mardis et al., 2009). Briefly, DNA was sheared (Covaris), end repaired (Lucigen), 
polyadenylated (Lucigen), and ligated to adapters (Illumina) for paired-end data generation. 
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DNA sequencing was performed on the Illumina Genome Analyzer II and generated between 
114 and 260 Gbp of sequence data for each tissue studied and haploid coverage ranging from 
29.24 to 72.17.  
 
Somatic Alteration Detection Pipeline 
Reads were aligned to human reference build 36 
(ftp://ftp.ncbi.nih.gov/genomes/H_sapiens/ARCHIVE/BUILD.36.3/special_requests/assembly_va
riants/; BWA 0.5.5, http://sourceforge.net/projects/bio-bwa/), merged into a single binary 
alignment map (BAM) file, with duplicate reads removed using Picard 1.07 
(http://broadinstitute.github.io/picard/) by the established pipeline, as previously reported 
(Govindan et al., 2012). To determine somatic variants, we utilized samtools (Li et al., 2009) 
followed by SomaticSniper using a somatic score ≥40 and mapping quality ≥40 (Larson et al., 
2012, 2014). Additional screening against dbSNP was used to remove probable germline 
variants (Ley et al., 2008; Sherry et al., 2001). Indels were identified with Pindel (Ye et al., 2009) 
and GATK (McKenna et al., 2010). All variants were further annotated as previously described 
(Ley et al., 2008; Mardis et al., 2009) using VarScan2 (Koboldt et al., 2012) (parameters: --min-
coverage = 30, --min-var-freq = 0.08, --normal-purity = 1, --p-value = 0.10, --somatic-p-value = 
0.001, --validation = 1) to classify mutations as reference, germline, somatic, or resulting from 
loss of heterozygosity (LOH). A Bayesian classifier was applied to retain the somatic variants 
with a binomial log-likelihood of at least 3 (parameters: --llr-cutoff = 3, --tumor-purity = 0.95). 
False positives, as determined by strand specificity, consistent positions near the ends of reads, 
and poorly mapped qualities, were removed. 
Mutations were assigned to four tiers: (1) coding, (2) conserved or regulatory, (3) unique 
noncoding, and (4) repetitive noncoding regions.  
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Structural variants (SVs) were called with BreakDancer (Chen et al., 2009) and filtered 
using TIGRA_SV (Chen et al., 2014). Somatic copy number alterations were detected using 
CopyCat v1.6.9 (https://github.com/chrisamiller/copycat), with 10,000 bp windows and default 
parameters.  
 
Experimental Validation of Mutations 
 Genotypes from Illumina Human OmniExpress BeadChip SNP arrays were used to 
compare and confirm the heterozygous SNPs detected in the analyzed WGS data.  
 Putative indels of 1-2bp were converted to BED format and provided as target intervals for 
the GATK IndelRealigner (DePristo et al., 2011; McKenna et al., 2010). The primary, 
metastases, and matched normal breast tissue for each patient were then realigned to these 
BED files independently. To validate the original predictions, we developed a matching 
algorithm that attempts to match Varscan validation calls with the original indel predictions, as 
described (Govindan et al., 2012). All validated somatic indels were then manually reviewed 
using Integrative Genomics Viewer (IGV) (Thorvaldsdóttir et al., 2013). 
 Indels of 3–100 bp were assembled using TIGRA (Chen et al., 2014) and validated as 
previously described (Govindan et al., 2012). Variants that passed the strict validation were 
manually reviewed. 
 Custom sequence capture validation was performed with Roche NimbleGen arrays for 
97.3% of the Tier 1–3 somatic alterations and 68.6% of the SVs. Whole genome amplified DNA 
was prepared for Illumina sequencing according to the manufacturer’s protocol (Illumina, San 
Diego, California). DNA was fragmented with the Covaris S2 DNA Sonicator (Covaris, Woburn, 
Massachusetts), adapter-ligated, SPRI-bead cleaned, and PCR amplified. One µg of the 300–
500 bp fragments was hybridized to the NimbleGen HD2 probe set according to the 
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manufacturer’s protocol (Nimblegen, Madison, Wisconsin). Following hybridization, the library 
was PCR amplified for 16 cycles and quantified with the KAPA SYBR FAST qPCR Kit (KAPA 
Biosystems, Woburn, Massachusetts) such that 180,000 clusters were sequenced per lane of 
the Illumina GAIIx. 
Reads were mapped to the NCBI Build 36 reference WUGSC Variant, a subset of the 
NCBI36 sequences from Ensembl Release 46 
(ftp://ftp.ncbi.nih.gov/genomes/H_sapiens/ARCHIVE/BUILD.36.3/special_requests/assembly_va
riants/). 
  The validation sequence was aligned with BWA v0.5.9, and duplicate reads were marked 
using Picard (v1.29). Updated versions of BWA and Picard were used for increased alignment 
speed and variant detection efficiency. The RefCov package was used to evaluate the coverage 
of target sequences (http://gmt.genome.wustl.edu/packages/refcov/).  
Capture validation reads and mates were mapped to both the assembled SV contigs and 
the reference with CrossMatch (version 1.080721). The threshold for an acceptable alignment is 
≤1 mismatch at either end, ≤1% substitutions, 1% indels and a CrossMatch score ≥ 50.  An SV-
supporting read is required to span the breakpoint on the SV contig,  align to 10 bases flanking 
on each side of the breakpoint, and have no alignment to the reference above the minimum 
alignment criteria. The somatic status of each SV was determined using Fisher’s exact test 
between the matched tumor and normal sample. All validated calls were manually reviewed.  
UNCeqR (Wilkerson et al., 2014) was run on validation mode: the algorithm accepts as 
input a set of predetermined mutations, such as a list of mutations generated from WGS/WES, 
and then looks within the RNA-seq data for expression evidence of the variants. Tier 1 
mutations were input into UNCeqR along with the RNA-seq BAM files aligned with MapSplice 
(Wang et al., 2010). UNCeqR then calculated the number of reads of the reference and variant 
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alleles at each position interrogated. Mutations with less than 5 reads were considered as 0. 
RNA variant allele fraction (VAF) was calculated as variant allele reads/total reads.  
 
Clonality Analyses  
 The clonal structure of each tumor was inferred with SciClone (version 1.0.7) (Miller et al., 
2014), with parameters minDepth = 75, copyNumberMargins = 0.25, and maximumClusters = 
20. Single nucleotide variants (SNVs) in copy number altered regions or with evidence of 
complete or partial LOH were reviewed and excluded. Phylogeny was inferred using the 
clonevol R package (https://github.com/hdng/clonevol) with default parameters. 
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Results 
Case Histories  
Patient A1 was a 65-y-old white woman who presented with stage IV TNBC and synchronous 
metastases to the bone of the vertebral column (spinal), lung, adrenal gland, liver, and lymph 
nodes. She was treated with radiation therapy to the breast, whole brain, and C3/T2 of the 
spine, had one cycle of palliative paclitaxel without response, and died of disease 2-mo post-
diagnosis. Patient A7 was a 60-y-old African-American woman diagnosed with a 5-cm stage IIIA 
TNBC. A pretreatment primary tumor biopsy was collected as a part of an existing tissue 
collection protocol (LCCC 9819, NCT01000883), and she subsequently received neoadjuvant 
doxorubicin plus cyclophosphamide followed by paclitaxel. She underwent mastectomy with 
T2N2 residual disease, followed by adjuvant radiation therapy to the chest wall (SCV fossa and 
axillary nodes). Patient A7 remained without evidence of disease recurrence for 17 months 
before presenting with metastases to the brain, kidney, liver, lung, and ribs. She received single-
agent capecitabine for 4 months, with an initial minimal response and then progression both 
systemically and in the central nervous system (CNS), followed by a single cycle of carboplatin 
that was discontinued because of poor tolerability and evidence of rapid progression. Patient A7 
died of disease 8 months after her metastatic progression. For both patients, fresh frozen tissue 
was collected at autopsy from primary tumor, distant metastases, and adjacent normal 
(nonmalignant breast) tissue, except for the primary tumor specimen that was obtained before 
neoadjuvant treatment was initiated in patient A7 (Figure 2.1).  
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Figure 2.1. Clinical history and distribution of metastases from patients A1 and A7. 
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Whole Genome Sequencing Coverage and Mutation 
 For the matched normal tissues, primary tumor (pre-treatment biopsy for A7), and distant 
metastases from patients A1 and A7, we performed DNA whole genome paired-end 
sequencing. For A7, we derived 138.38, 118.76, 260.93, 128.69, 204.34, 201.66, and 156.82 
Gbp of sequencing data from normal tissue, primary tumor, liver, lung, rib, kidney, and brain 
metastases, respectively, with corresponding haploid coverages ranging from 33.17X to 70.19X. 
For A1, we generated 265.53, 134.07, 115.85, 210.45, 114.31, and 131.03 Gbp of data from 
normal tissue, primary tumor, liver, lung, adrenal, and spinal cord metastases, respectively, with 
haploid coverage ranging from 30X to 72.16X. 
 Candidate somatic changes were predicted using multiple algorithms. Confirmatory testing 
of heterozygous mutations with genotype arrays confirmed bi-allelic detection of 80.47% to 
89.63% in all samples. Candidate mutations were further validated with capture probes 
corresponding to all putative somatic SNVs and small insertions/deletions (indels) that overlap 
with coding exons, splice sites, and RNA genes (Tier 1), a number of high-confidence SNVs and 
indels in noncoding conserved or regulatory regions (Tier 2), and nonrepetitive regions of the 
human genome (Tier 3). In addition, we included predicted somatic SVs for validation. We 
obtained 40X haploid reference coverage for 87.48% to 94.02% of the targeted sites. For A1, 73 
Tier 1 point mutations, 1 Tier 1 indel, and 53 somatic SVs were confirmed across the primary 
tumor and metastases. For A7, there were 150 Tier 1 point mutations, 47 indels, and 40 SVs 
confirmed in the primary tumor and five metastatic samples.  
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Genomic Relatedness of Primary Tumors and Metastases 
Common gene expression patterns throughout metastasis. In order to study the degree of 
relatedness between a primary tumor and its metastases, we performed mRNA-seq gene 
expression analyses followed by hierarchical clustering analysis using a breast cancer “intrinsic” 
gene list (Parker et al., 2009) including data from the 11 specimens studied here and 1,100 
breast tumors from the Cancer Genome Atlas (TCGA) (Ciriello et al., 2015). Regardless of 
physical or temporal distance between the primary and its metastases, all tumors from these 
two patients clustered tightly together by patient (Figure 2.2). By gene expression analysis using 
the PAM50 intrinsic breast cancer subtype predictor (Parker et al., 2009), the primary tumors 
and metastases all maintained a basal-like subtype phenotype and clustered with the basal-like 
samples from TCGA (Figure 2.2B); previous research has demonstrated a high correlation 
among primaries and matched metastases by microarray gene expression (Bertucci et al., 
2016; Harrell et al., 2012).  
In patient A1, in whom the primary tumor and distant metastases were found 
synchronously and who had limited exposure to chemotherapy and radiation prior to death, the 
gene expression hierarchical cluster node correlation for the primary and the four metastases 
was 0.77 (Figure 2.2C).  In patient A7, who received neoadjuvant chemotherapy and radiation 
and had a 17-mo interval separating the discovery of the primary tumor and distant metastases, 
the node correlation for the six samples was 0.79 (Figure 2.2C). This demonstrates that subtype 
was maintained throughout metastasis in these two patients and that, as we and others have 
shown (Bertucci et al., 2016; Harrell et al., 2012), distant metastases are typically much more 
similar to their original primary than they are to other primary tumors or metastases from other 
patients.  
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Figure 2.2. Molecular relatedness of matched primary and metastases. (A) Hierarchical 
clustering of patient A1 and A7’s tumors with 1,100 TCGA Primary samples and 98 normal 
breast samples analyzed using a breast cancer intrinsic gene list. The color bars under the 
dendrogram indicate (i) where A1 (red) and A7 (blue) specimens are clustered and (ii) the 
PAM50 subtype of each sample (basal-like, red; HER2-enriched, pink; luminal A, dark blue; 
luminal B, light blue; and normal-like, green). (B) The position of A1 (red) and the position of A7 
(blue) within the basal-like cluster are highlighted. (C) The relationship of the primary and 
metastases for each patient based upon gene expression patterns. 
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Functional mutations are maintained and enriched during metastasis. We next studied 
DNA-based data from each primary tumor and its multiple distant metastases. In patient A1, 54 
genes were mutated with a VAF greater than 0.5% in the primary tumor (13 non-silent mutations 
were in the Catalogue of Somatic Mutations in Cancer [COSMIC] (Forbes et al., 2015)) (S4 
Table). Almost every Tier 1 mutation present in the A1 primary tumor was identified in one or 
more of the metastases (52/54), and in many cases the VAF was enriched in the metastasis 
(median: 5-fold enrichment, average: 8.8-fold, range: 1- to 38-fold; Figure 2.3A). Eleven mutated 
genes were shared among the primary and all matched metastases: TARBP1, FCRL1, XIRP1, 
TRMT1, PANX3, MYSM1, PHLDB3, TBC1D25, LOC284288, MDS2, and TP53. The adrenal 
metastasis and spinal metastasis contained the most unique SNVs, with seven and nine, 
respectively. The liver metastasis and lung metastasis did not have any private mutations at a 
VAF > 1%, although the lung metastasis did share two mutations with the adrenal metastasis 
that were not observed in the primary.   
In patient A7, 75 Tier 1 genes were mutated with a VAF ≥ 0.4% in the primary tumor (14 
of these non-silent mutations were in COSMIC) (Figure 2.3B). The VAF in all of the metastases 
had a median enrichment of 1.4-fold, closer to the primary tumor than in patient A1. All of the 
mutations identified in the primary tumor were detected in at least one metastasis, and 65 
mutations, including mutations in RUNX1T1, ADGRB2, KMT2C, RP1, TP53, and AKT3, were 
shared across the primary and all matched metastases. There were 75 mutations identified in 
one or more of the metastases that were not observed in the primary tumor (8 of these nonsilent 
mutations also were in COSMIC). The majority of these metastasis-specific mutations (54/75) 
were present in two or more metastases. Of the 21 mutations private to a single metastasis, the 
liver and kidney metastases had the most, with 7 and 8 private mutations, respectively. The rib 
metastasis contained no unique mutations.  
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Figure 2.3. Heat map of the DNA variant allele frequency of Tier 1 mutations in patients A1 
and A7. The vertical bar to the left of each heat map designates genes shared with the primary 
and metastases (black), genes mutated in metastases but not in the primary (blue), and genes 
private to a single individual metastasis (red) in (A) Patient A1 and (B) Patient A7. 
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TP53 as a common driver of metastasis. TP53 alterations are frequently observed in basal-
like breast cancers (Cancer Genome Atlas, 2012). TP53 was the only shared somatic mutated 
gene between the two patients and was present in every tumor specimen sequenced. Close 
examination of patient A1 data identified an 11 bp deletion in TP53 that was common to all 
samples (Figure 2.4). In patient A7, the TP53 missense mutation H168R had a greater than 
68% VAF in all tumors except the brain metastasis (31%). While this exact mutation was not 
observed in the TCGA breast cohort, a missense mutation was identified at the same position in 
one case (H168P) (Cerami et al., 2012; Gao et al., 2013), supporting the likelihood that 
alteration of TP53 is a founding event critical for the development of basal-like breast cancer 
(Shah et al., 2012) and subsequent metastasis.  
 
Mutations established early tend to be expressed and enriched in metastasis. We 
examined the mRNA expression data for evidence of expression of the somatic point mutations 
in primary tumors and metastases. Interestingly, mutations shared between the primary and 
metastatic tumors were more likely to be expressed (Figure 2.5, black dots) and were 
expressed at higher levels than mutations unique to metastasis (Figure 2.5, blue dots). In 
patient A1, 21/52 (40%) of the mutations established in the primary were expressed in the 
metastases (Figure 2.5A, black dots). In patient A7, 47/75 (63%) of the mutations established in 
the primary were expressed both in the primary and metastases (Figure 2.5B, black dots). 
Fewer mutations were detected only in the metastases, and those mutated transcripts 
had lower RNA expression than mutations shared with the primary (Figure 2.5, blue dots). In 
patient A1, 2/3 mutations shared among more than one metastasis but not in the primary tumor 
were expressed (Figure 2.5A, blue dots), while only 4/18 private mutations (detected only in one 
tumor) were expressed (Figure 2.5A, red dots). In patient A7, 23/54 (43%) of the mutations that 
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were shared across the metastases but not with the primary tumor were expressed, and 8/21 
(38%) of the private mutations were expressed (Figure 2.5B). 
Interestingly, many of the expressed metastasis-specific mutations occur in genes that 
are involved in DNA damage responses, RNA processing, and degradation of the extracellular 
matrix (ECM). In patient A1, metastasis-specific mutations included FANCF and SMC6 (DNA 
double-stranded break repair), DDX6 (promotes mRNA degradation), and HYAL3 (degrades 
hyaluronan in the ECM) (Rebhan et al., 1997). In patient A7, AQR, DOCK6, and HLTF were 
shared across metastases and expressed. Metastasis-specific mutations in patient A7 included 
CASC3 (the core of the exon junction complex), TIMP3 (degrades ECM), and LAMA5 (part of 
the ECM) (Rebhan et al., 1997). These could represent convergent evolutionary paths to the 
resistance of DNA damaging agents and promotion of cell mobility and survival.  
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Figure 2.4. TP53 Deletion in A1. Genome view of the 11 bp deletion of TP53 in Patient A1 at 
chr17:7,579,474 to chr17:7,579,485, present in the primary tumor and all of the metastases. 
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Figure 2.5. Gene expression of variant alleles. Variant allele fractions (VAFs) of each point 
mutation were determined from mRNA-sequencing data and compared to those from combined 
whole genome sequencing (WGS) and validation sequencing data. Gene variants shared in the 
primary and metastases (shared mutations, black), metastases but not primaries (metastases 
specific, blue), or only in one metastasis (private, red) in patients A1 (A) and A7 (B) are shown. 
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Structural variations tend to be established early in metastasis. To further explore the 
development of larger genomic alterations during metastasis, Circos plots were generated to 
illustrate the combined Tier 1 somatic mutations, DNA copy number alterations, and SVs for 
each sequenced tumor (patient A1: Figure 2.6; patient A7: Figure 2.7). These illustrate that, 
overall, SVs were mostly established in the primary tumor and maintained through the different 
metastatic processes. 
In patient A1, all 8 of the SVs in the primary tumor were shared with the metastases 
(Figure 2.6), including one that was specifically shared with the adrenal and liver metastases. 
The metastases had few additional interchromosomal SVs, and these were shared, except in 
the spinal metastasis. Interestingly, the spinal metastasis evolved to have many more 
rearrangements between chromosomes 2 and either 3, 8, 12, or 16. 
In patient A7, the brain and kidney metastases shared most interchromosomal SVs with 
the primary (Figure 2.7). The rib and liver metastases had three private SV alterations each (of 
a total of six and eight alterations, respectively), while the lung metastasis showed many more 
private interchromosomal SVs than the other metastatic samples. 
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Figure 2.6. DNA alterations of matched primary and metastases of patient A1. (A–F): Circos plot 
displays mutations, copy number, and structural rearrangements in the (A) primary, (B) spinal, 
(C) lung, (D) liver, and (E) adrenal metastases. Translocations with significant read coverage 
include shared (green) and private (red) interchromosomal and shared (purple) and private 
(blue) intrachromosomal translocations. 
 
Figure 2.7. Circos plots of matched primary and metastases of patient A7. Circos plots 
displaying mutations, copy number landscape, and structural rearrangements (order starting 
from outside) in the (A) primary, (B) rib, (C) kidney, (D) liver, (E) brain, and (F) lung metastases. 
Translocations with significant read coverage include shared (green) and private (red) 
interchromosomal and shared (purple) and private (blue) intrachromosomal translocations.  
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FBXW7-INPP4B fusion in patient A7. To confirm SVs, we created a modified genome that 
represented the possible new alignments in RNA space. Realigning A7 data to this map 
demonstrated expression of an FBXW7-RNF150 fusion gene observed in all A7 samples, 
indicating early fusion of this gene in the development of this patient’s breast cancer (Figure 
2.8). Interestingly, deletion of the last ten exons of FBXW7 was previously reported as a 
founding event in a basal-like breast cancer (Ding et al., 2010). The 5′ end of the fusion in 
patient A7 began at exon 3 or 4 of FBXW7, which likely inactivated FBXW7. The 3′ end of the 
fusion occurred just before RNF150, resulting in deletion of INPP4B. There was decreased RNA 
expression of INPP4B in this patient, further supporting the deletion of INPP4B by the FBXW7-
RNF150 fusion gene event. INPP4B has important implications in breast cancer that include 
DNA repair defects (Ip et al., 2015), increased genomic instability (Weigman et al., 2012), and 
inhibition of the PI3K pathway (Gewinner et al., 2009). 
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Figure 2.8. FBXW7 fusion. Representative illustration of FBXW7 fusion and INPP4B deletion in 
all tumors from A7. 
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Multiclonal Evolution of Metastasis in Two Patients with TNBC 
To understand the Darwinian evolution occurring in the primary tumor and throughout 
metastasis (Campbell et al., 2008), we established the subclonal relationships and phylogenetic 
trees for patient A1 (Figure 2.9, S6–S8 Figs) and patient A7 (Fig 5, S9–S10 Figs).  
Subclonality analysis using SciClone of the A1 patient samples demonstrates that the 
primary tumor predominantly contained clones 1, 3, 5, and 8, with very low allele fractions of 
minor clones 2, 4, and 7 (Figure 2.9,Figure 2.10A). Clone 1, established in the primary tumor, 
seeded all other metastases. Of the other major clones in the primary, clones 3 and 5 seeded 
the lung metastasis, while clone 3 additionally seeded the spinal metastasis. This metastasis 
then continued to evolve, developing private clone 9 (Figure 2.10A). These clones (3 and 5) 
were mutually exclusive with minor clone 2, which was found in the primary tumor, lung, liver, 
and adrenal metastases (Figure 2.11). Two of the minor clones in the primary tumor (clones 2 
and 4) became the dominant clones in the liver and adrenal metastases, with additional private 
subclonal evolution in the adrenal metastasis (clone 6). Interestingly, clone 7 was established in 
the primary tumor and also metastasized to the liver, but not to the adrenal, metastasis (Figure 
2.10B). Using ClonEvol, there were two potential models for clone 7 development that we were 
not able to fully resolve; either it evolved (1) from clone 4 (Figure 2.11) or (2) independently from 
clone 2 (Figure 2.12). This result demonstrates that the multiclonal metastatic potential residing 
in the primary tumor is maintained through metastasis. 
Importantly, patient A1 presented at stage IV and only received two doses of radiation 
and one cycle of single-agent taxane before death. Thus, her primary-to-metastatic disease 
likely is representative of the natural course of basal-like breast cancer rather than representing 
selection from the evolutionary pressure imposed by therapy.  
  
 
 
35 
 
Figure 2.9. SciClone analysis of A1. SciClone analysis of variant allele frequencies in copy 
number neutral regions of each tumor using Bayesian beta mixture modeling and multi-
dimensional clustering of tumors from patient A1. Multiple clones are shared in the primary and 
metastases, with Clone 1 in the primary and all matched metastases; Clone 2: primary, adrenal, 
and liver; Clone 3: primary, adrenal, and liver; Clone 4: primary, lung, and spine; Clone 5: 
primary, adrenal, and liver; Clone 6: primary and lung; Clone 7: adrenal; Clone 8: primary and 
liver; Clone 9: primary; and Clone 10: spinal. 
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Figure 2.10. Clonality analysis of each tumor from patient A1. VAFs among the primary and 
matched metastases in patient A1 (A) and a representative evolutionary tree (B) colored by 
subclone based on the clonality plots in panel A, with the width of the branch indicating the 
approximate percentage of that clone within the tumor. Clone 1 is established in the primary 
tumor and seeded all distant metastases. Clones 2 and 4 from the primary tumor seeded the 
liver and the adrenal gland, with clone 7 concurrently seeding the liver from the primary tumor. 
Clones 3 and 5 from the primary tumor seeded the lung, with clone 3 also seeding the spine. 
Private clones include clone 6, specific to the adrenal metastasis; clone 8, specific to the 
primary tumor; and clone 9, specific to the spinal metastasis. 
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Figure 2.11. ClonEvol analysis of A1. ClonEvol demonstrates that Clones 1 and 2 are founding 
clones that seed the distant metastases at different percentages. Clone 2 and Clone 3 are 
exclusive of one another, leading to separate lineages. The proportion of each clone is 
demonstrated by the width of the nested shapes. 
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Figure 2.12. Representative evolutionary tree of an alternative model of A1. ClonEvol predicted 
two possible evolutionary lineages of clones in patient A1. The first model is in Fig 5B. The 
alternative model demonstrating that Clone 7 is independent of Clone 4 is presented.  
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In patient A7, the subclonal structure was determined by SciClone (Figure 2.13), and a 
single model of evolution was suggested by ClonEvol (Figure 2.14). The primary tumor 
consisted of one main clone (Figure 2.15), seeding all other sites of metastasis at the highest 
VAF observed.  The main clone then diverged to two lineages, giving rise to clone 2 
predominantly in the liver, kidney, and rib and clone 4 predominantly in the lung and brain 
(Figure 2.15B). Clone 4 is present in the lung and brain metastases at an almost equivalent VAF 
to the founding clone 1. Clones 2 and 6 in the rib are also present at an almost equivalent VAF 
to clone 1; clones 2 and 6 are seen at a low VAF in the lung. These clonal data paint a complex 
picture with two possible explanations: either the split of clone 1 into clones 2 and 6 and clone 4 
occurred prior to metastatic spread (Solution A, Figure 2.15B) or these clones cross seeded 
from the rib metastasis to the lung metastasis (Solution B, Figure 2.15B). Clone 2 further 
evolved to clones 3 and 5 in the liver and kidney metastases. We favor the first hypothesis, 
namely that clone 2 in the rib, liver, and kidney metastases is at a VAF equivalent to the 
founding clone, indicating that the evolution of this clone occurred before metastatic seeding. All 
metastases aside from the rib metastasis also contained private subclones. 
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Figure 2.13. SciClone analysis of only copy number neutral regions demonstrates multiclonal 
seeding of metastases. The Lung metastasis contains both branches of the clonal tree, 
predominantly containing Clone 4 but with a small fraction of Clone 2. In contrast, the rib 
metastasis contains predominantly Clone 2 with a small minority of Clone 3. Private clones are 
seen in all metastases. 
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Figure 2.14. Clonevol analysis of A7. ClonEvol of the copy number neutral mutations from 
SciClone analysis demonstrates one founding clone leading to a branched pattern of Clones 2 
and 4. Private clones are present in all metastases. 
 
  
 
 
42 
 
Figure 2.15. Clonality analysis of each tumor from patient A7. Clonality shared among the 
primary tumor and matched metastases in patient A7 (A) and the representative evolutionary 
tree (B) colored by subclone identity based on the clonality plots in panel A, with the width 
representative of the percentage of the clone within that tumor. Clone 1 was established in the 
primary tumor and maintained through metastatic spread in every tumor. Clone 2 was present in 
the liver, kidney, and rib and at a low frequency in the lung, while clones 3 and 5 were 
additionally shared by the liver and kidney metastases. Clone 6 was present in the rib and a low 
frequency in the lung metastases. Brain and lung metastases shared clone 4. Each tumor had a 
private clone not shared with any other tumor: clone 7 specific to the lung, clone 8 specific to the 
kidney, clone 9 specific to the liver, and clone 10 private to the brain. 
 
 
43 
Discussion 
Whole genome sequencing and mRNA sequencing of two TNBC/basal-like breast 
cancer patients with primary tumors and multiple matched metastases demonstrated significant 
genetic similarity between the primary breast cancers and their matched metastases. Patient A1 
demonstrated significant intratumoral heterogeneity established in the primary tumor and 
multiclonal seeding of metastasis. Interestingly, patient A7 possibly contained a more 
homogenous primary breast cancer that then led to diverse, heterogeneous metastases. Even 
though there is continued evolution, the acquisition of mutations private to a single metastasis 
likely had limited impact on the metastatic potential, as these mutations were rarely expressed 
or were expressed at low levels. In contrast to earlier findings in renal cell carcinoma of 
monoclonal metastasis seeding (Gerlinger et al., 2012), basal-like breast cancer metastases 
can be the result of multiclonal seeding of cells established in the primary. The results 
presented here are inconsistent with a single cell of a primary breast cancer seeding a distant 
metastasis (Navin et al., 2011). Herein, we describe an example of multiple subclones that 
resided within a primary tumor followed by multiclonal seeding of all distant metastases as well 
as a common disruption of TP53. 
In both patients, relatively few mutations occurred once the tumor cells left the primary 
site, and of those that did alter protein coding sequences, the mutations were not highly 
expressed at the RNA level in general. The high correlation of gene expression among 
primaries and matched metastases illustrates that subtype is typically maintained throughout 
metastasis (Harrell et al., 2012), and that specific intrinsic subtypes have an inherent tendency 
to metastasize to specific organs (Harrell et al., 2012; Smid et al., 2008). Taken together, these 
results suggest that the metastatic potential was present within the primary tumor of these two 
basal-like breast cancer patients. Here, we uncover a genetic explanation for the close 
 
 
44 
correlation of gene expression in metastases and matched primaries—namely that, in the two 
cases examined, the samples from a given individual were much more genetically similar than 
they were dissimilar, both on the DNA and RNA levels. 
While the majority of genetic alterations present in metastases were shared with the 
matched primary cancer in these two patients examined, we also identified a significant amount 
of intratumoral heterogeneity, evident because multiple subclones were detected within each 
metastasis. Patient A1 demonstrates that more than one subclone from the primary seeded 
each metastasis, and the intratumoral heterogeneity in the primary tumor setting was mostly 
reflected in each metastasis. In patient A7, the lung metastasis exhibited diverse intratumoral 
heterogeneity, with two small subclones (2 and 6) found at high frequency in three of the other 
metastases. There are two possible explanations for the complex clonal patterns seen in patient 
A7: either the two dominant clones (clones 2 and 4) were established in the primary and were 
not sampled in the piece of the primary tumor that was actually sequenced, or clones 2 and 6 in 
the rib cross seeded into the lung metastasis. While one metastasis seeding another metastasis 
has been previously demonstrated in prostate cancer (Gundem et al., 2015), we also recognize 
that the A7 primary breast cancer likely had spatial heterogeneity that was not fully captured by 
our sequencing (Yates et al., 2015). In fact, the A7 primary breast cancer piece sequenced was 
a skin punch biopsy taken from a 5 cm primary breast cancer, rather than a tumor resection. 
Hence, samples from multiple portions of this tumor were not sequenced. Of the two 
possibilities, the most parsimonious explanation for the observations relevant to patient A7 is 
that multiclonal seeding of the metastases did occur and that our limited sample did not permit 
detection of clones 2 and 6. Hence, only subsequent deep sequencing of additional portions of 
the A7 tumor would resolve the issue of monoclonal versus multiclonal seeding from the 
primary. Unfortunately, no additional specimens exist for this patient. Regardless of this, in 
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patient A7 multiple multiclonal seeding events were discovered, such as the rib metastasis 
seeding the kidney and liver. 
The genetic heterogeneity in both of the primary tumors and the resulting metastases 
may explain why many metastatic TNBC patients fail to have a durable treatment response and 
instead progress within a few years (Anders and Carey, 2008). In particular, heterogeneity 
provides for a wealth of individual genotypes, thus yielding a genetic diversity from which 
chemotherapy resistance may arise. Treatment has been shown to select for therapy-resistant 
clones in primary breast cancer (Juric et al., 2015; Li et al., 2013; Miller et al., 2016), and 
therapy can select for subclones in the metastatic setting. 
While our studies provided evidence of multiclonal seeding of metastasis in these two 
patients, both with basal-like breast cancer, our results may or may not apply to a larger cohort 
of patients with basal-like breast cancers, to other subtypes of breast cancers, or to other 
cancer types. Even within the poor-prognosis basal-like subtype, patients often receive many 
more lines of therapy and have more favorable responses to their therapies for a longer duration 
than the two patients presented here. Furthermore, patients with luminal and HER2-enriched 
breast cancer have comparatively more opportunities to benefit from targeted therapies such as 
tamoxifen, aromatase inhibitors, and/or HER2 agonists such as trastuzumab, lapatinib, or 
pertuzumab. Since neither patient A1 nor A7 was treated with targeted therapies, there were 
different selective pressures in the metastatic setting compared to current standard of care for 
ER+ and HER2+ patients.  
The basal-like subtype is a highly aggressive cancer that often metastasizes to the lung 
and brain within 5 y of diagnosis. This is in contrast to luminal A breast cancers, which are 
typically more indolent, are less likely to progress to stage IV, and typically metastasize first to 
the bone (Haque et al., 2012). The difference in these patterns of relapse and the timing with 
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which they occur suggest fundamental differences in disease progression between the subtypes 
(Ellis et al., 2012) within the context of drastically different treatment strategies. Continued 
analyses of larger datasets representing each of the subtypes and patients with varying clinical 
histories will be necessary to identify consistently altered genes to define early versus late 
drivers, metastasis-site specific alterations, and differences among the mechanism of 
metastasis across various subtypes of breast cancer. 
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CHAPTER 3 – THE EVOLUTION OF LETHAL BREAST CANCER METASTASIS: 
MULTICLONAL SEEDING DRIVEN BY TP53 AND COPY NUMBER ALTERATIONS 
Preface 
 This work is currently under review and is a first author manuscript. The UNC Tumor 
Donation Program was started by Dr. Lisa Carey, with tissues collected by Niamh Kieran, Julie 
Benbow, and Amy Garret. Autopsies were performed by Vincent Moylan and Claudia Brady. 
Tissue quality control was performed by pathologists. Chad Livasy and Leigh Thorne. DNA and 
RNA isolation, library preparation, and sequencing was performed mostly by Dr. Xiaping He with 
the latter DNA samples done by me. Sequencing data was mapped by Alan Hoyle and Joel 
Parker. Copy number was evaluated by Mengjie Chen. Droplet PCR of ESR1 mutations was 
performed by Sunil Kumar and Gaorav Gupta. I performed all scientific investigation of both the 
RNA and DNA sequencing analyses, with significant oversight and mentorship from Katherine 
Hoadley, Joel Parker, Elaine Mardis, Lisa Carey, Carey Anders, and Charles Perou. I designed 
the figures, supplemental data, and written text of this manuscript. 
 
Introduction 
Breast cancer is the second leading cause of cancer related death in women and is 
typically caused by metastasis. Breast cancer is a heterogeneous disease comprised of multiple 
“intrinsic” expression-based subtypes (Perou et al., 2000), wherein the subtype predicts future 
sites of recurrence and survival (Harrell et al., 2012; Smid et al., 2008). While this evidence 
strongly supports the hypothesis that the primary tumor contains information about metastatic 
potential, the factors responsible for this metastatic potential are still not well understood.  
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It also remains unknown whether metastasis is the result of a single cell from the primary 
tumor circulating in the blood to seed and survive at distant sites (i.e. monoclonal seeding), or 
instead results from a collection of multiple cells of the primary that seed together and survive at 
distant sites (i.e. multiclonal seeding). Additionally, it is unclear when the ability to metastasize is 
acquired: by the original primary cells, over time during some dormancy period that follows 
treatment, or with adaptation at the final site of metastasis. Understanding the heterogeneity of 
metastatic sites, for example whether they correspond genetically to one or multiple clones from 
the primary tumor, could more accurately inform treatment decisions.  
Several recent studies in other tumor types have demonstrated both single clones 
leaving the primary to seed distant metastases (Gerlinger et al., 2012) and multiclonal seeding 
(Gundem et al., 2015; Maddipati and Stanger, 2015). In small cohorts of breast cancer patients, 
previous breast cancer studies have also demonstrated both monoclonal (Ding et al., 2010; 
Krøigård et al., 2015) and multiclonal (Murtaza et al., 2015) seeding of single, matched 
metastatic sites. Multiregional sequencing of breast cancer has demonstrated that significant 
heterogeneity existed within 8/12 primary tumors (Yates et al., 2015). Brastianos and colleagues 
demonstrated continued acquisition of new driver mutations in the context of brain metastases 
(Brastianos et al., 2015). Using two patients and whole genome sequencing of multiple matched 
metastases and primaries, we previously reported multiclonal seeding of triple negative, basal-
like breast cancers (Hoadley et al., 2016). These studies were, however, limited by studying 
small cohorts of patients and typically only one or two matched metastatic sites per patient. 
Additionally, these studies defined “genetic drivers” as genes previously shown in large 
scale sequencing projects to be significantly mutated above the background rate that is 
expected by chance (Cancer Genome Atlas, 2012; Ciriello et al., 2015; Dees et al., 2012a; 
Lawrence et al., 2013). The actual biological or functional impact of these alterations in 
individual patients therefore was not measured. Computational approaches incorporating gene 
expression from RNAseq data and known protein interaction networks could help to predict the 
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functional impact of individual DNA-based somatic alterations (Hou and Ma, 2014). Previous 
work has demonstrated the power of integrating gene expression and DNA alterations to define 
unique driver sets beyond mutational background (Silva et al., 2015). By employing the 
DawnRank method to determine the functional impact of mutations and copy number 
alterations, we can empirically define drivers on an individual tumor basis as well as the timing 
with which they occur during the development of breast cancer metastasis. 
Here, we present the underlying evolutionary processes of breast cancer metastasis in a 
large cohort of primaries with matched multiple metastases per patient. Utilizing a Rapid 
Autopsy Program established at the University of North Carolina at Chapel Hill, we have 
collected matched primary and metastatic breast cancers from 16 individuals and performed 
RNA-sequencing (RNAseq) and DNA whole exome sequencing on the primary, 67 matched 
metastases (2-7 per patient) and a matched normal tissue comparator for each patient. We 
examine the clonal evolution of metastasis within each patient, copy number and mutational 
spectrum of the metastatic process in a subtype-specific manner, and apply a novel 
computational approach that integrates RNA and DNA sequencing data to identify genomic 
drivers. These results demonstrate the genetic diversity of the metastatic process and highlight 
the potential of using the primary tumor data as a means of targeting metastases. 
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Methods 
Patient consent and tissue processing 
Tumor tissue was obtained from metastatic breast cancer patients who consented to 
Rapid Autopsy at the University of North Carolina prior to death. Primary, metastatic, and 
normal tissue were taken within 6 hours of death for all metastatic sites, both known and found, 
at time of autopsy. Tissues were frozen in the -80C freezer, and RNA and DNA were isolated 
from each tissue using Qiagen RNAeasy and DNAeasy kits, respectively, according to the 
manufacturer protocols (Valencia, CA). Primary breast cancer tissues taken at diagnosis were 
also acquired as available. Archived tissues in formalin-fixed paraffin-embedded (FFPE) tissues 
had total RNA isolated with Roche High Pure RNA paraffin kit Cat #03270289001 and DNA 
isolated with the Maxwell 16 FFPE Tissue LEV DNA Purification Kit (San Diego, CA). Quality of 
RNA was checked with the Agilent BioAnalyzer RNA 6000 Nano Kit (Santa Clara, CA). 
DNA Whole Exome Sequencing 
DNA was prepared for sequencing with the Agilent SureSelect XT library protocol (Santa 
Clara, CA). Fresh-frozen tumors were processed according to manufacturer’s protocol 3ug 
input, while FFPE tumors were processed with the low-volume input according to 
manufacturer’s protocol for 200 ng input. DNA libraries were captured and amplified with Agilent 
SureSelect Human All Exon v5 or v6 (Santa Clara, CA) according to the manufacturer’s 
protocol. Quality of both DNA libraries and DNA exome capture quality and concentration were 
quantified with Agilent ScreenTape DNA 1000 and High Sensitivity D1000 respectively (Santa 
Clara, CA). 
2x100 bp paired-end sequence data was generated from the Illumina HiSeq 2500 for 
each tumor or normal sample with 3 samples per lane. Illumina reads were mapped to the NCBI 
Build 36 reference sequence with BWA (Li and Durbin, 2009), realigned with ABRA (Mose et al., 
2014), processed by biobambam2 (Tischler and Leonard, 2014), and called as somatic variants 
with STRELKA (Saunders et al., 2012).  
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We used minor allele frequency of highly variable SNPs in the general population for 
sample identity. All samples had an expected 87-100% identity with tumors from the same 
patient.  
Copy number was called with SynthEx (Silva GO et al., manuscript in preparation). 
Briefly, the ratio of on-target and off-target exome reads of tumor were compared to a normal 
selected from the dataset by highest degree of similarity in library size and fold enrichment. 
Segment level ratios were calculated and log2 transformed. Copy number levels greater than 
0.25 were considered as gains, and less than -0.32 as losses. 
RNA Sequencing 
Fresh-frozen (FF) RNA was prepared for sequencing with Illumina TruSeq polyA Select 
protocol. If libraries failed the protocol, they were then prepared with Illumina TruSeq RiboZero 
Gold protocol according to the manufacturer’s protocol. FFPE RNA was prepared with Illumina 
TruSeq FFPE RiboZero Gold protocol according to the manufacturer’s protocol. RNA libraries 
were sequenced as 2x50 base-paired end read with two samples per lane on an Illumina HiSeq 
2500 sequencers. Reads were aligned with MapSplice (Wang et al., 2010), genes values were 
quantitated with RSEM (Li and Dewey, 2011), and counts were upper quartile normalized and 
log2 transformed for analysis. 
Because of bias in FFPE and Total RNASeq data as compared to mRNAseq data, a 
normalization vector was calculated. Previously published matched samples of FFPE, total 
RNAseq, and mRNA sequenced samples with the same protocol were used to find the mean 
difference for each gene across each platform (Zhao et al., 2014). This was then applied to total 
RNASeq runs where a gene by gene adjustment was made in the total RNAseq samples. 
Droplet PCR for ESR1 Mutations 
Digital droplet PCR for wild-type (WT) and four hotspot ESR1 alleles (D538G, Y537C, 
Y537S, and Y537N) was performed using the Raindrop Source and Sense instruments 
(RaindanceTM Technologies, Billerica, MA). Primers for a 75bp amplicon that includes these 
 
 
52 
hotspot mutations were used in conjunction with locked nucleic acid Taqman probes for wild-
type (conjugated to TET) or mutant ESR1 alleles (conjugated to FAM), purchased from 
Integrated DNA Technologies (IDT, Coralville, IA). The multiplexed genotyping reaction was 
validated using synthesized 125bp DNA fragments (gBlocks, IDT, Coralville, IA). Details of 
primer and probe sequences are available upon request. TaqMan Genotyping Master Mix 
(Applied Biosystems, Foster City, CA) was used for 10-100 ng of Covaris-sheared genomic 
DNA in a 50 µl reaction volume. After PCR amplification in a thermocycler (C1000 Touch™ 
Thermal Cycler, Bio-Rad®, Hercules, CA), the emulsion was analyzed on the Raindrop Sense 
instrument (RainDanceTM Technologies, Billerica, MA) to measure the end-point fluorescence 
signal from each droplet using standard manufacturer’s protocols. The fluorescence intensity 
and duration for each droplet in the FAM and TET channels were analyzed using RainDrop 
Analyst Software II (RainDanceTM Technologies, Billerica, MA). Two-dimensional (FAM and TET 
intensity) plots were made for each sample and gates were used to define graphical areas with 
specific fluorescence properties. The number of droplet events specific for WT or mutant ESR1 
alleles was used to calculate the mutation frequency.  
 
Computational Analyses 
Hierarchical Clustering of Gene Expression. TCGA 1098 primary breast cancers (Ciriello et 
al., 2015) were merged with tissues from this study and median centered. Correlation centered 
hierarchical clustering of the median centered dataset with the PAM50 50 genes was performed 
with Cluster and visualized with Java TreeView. 
Computational re-interrogation of somatic mutations in Related Tumors. Low read 
coverage or low tumor cell purity can cause our rigorous somatic mutation caller to miss 
mutations (Mose et al., 2014; Wilkerson et al., 2014). Thus, we examined high-confident 
somatic mutations from a related individual in all tumors from that patient. First, all of the 
somatic mutations from the tumors within one patient were collapsed into one vector, excluding 
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any guanine to adenine or cytosine to thymine mutations from FFPE tissues. For each mutation 
from a single patient, we then counted the mutant and reference alleles at that position from the 
original BAM file of each tumor from that patient. Variant Allele Fractions (VAF, alternate 
counts/total read counts) were recalculated from the new calls. All mutations from the dataset 
were interrogated in the normal sequence for all tumors in this dataset to account for false 
positives. Mutations with variant allele frequencies greater than 20% in at least two normal 
tissues from unrelated patients were excluded from future analyses. 
DawnRank. We generated a binary matrix of 0 indicating no alteration and 1 indicating any 
alteration (mutation or copy number) for genes in the published DawnRank network (Hou and 
Ma, 2014). We combined TCGA log2 transformed normalized RNASeq data with RAP RNASeq 
data, median centered the data for each gene, and further transformed scores to the absolute 
value. DawnRank was then run for each individual tumor with a mu = 3. DawnRank scores were 
saved, and the top 5% of scores within each tumor were considered to be candidate drivers. 
These candidate drivers were then filtered by non-silent mutations and copy number laterations 
such that if an alteration was present, it was then identified as a driver.  
RNA Interrogation of DNA Mutations. Using the ‘union’ list of mutations for each patient, 
UNCeqR (Wilkerson et al., 2014) was employed to count the number of mutated reads from the 
RNA BAMs at each position within a patient. Mutations with read counts from non-normalized 
RNA counts less than 5 reads in the RNA were considered to be 0. Mutations within each tumor 
were only considered if at least 5 reads of that gene were detected with RNASeq. Any genes in 
which the RNA gene expression of the gene was less than 5 were removed from the total 
number of DNA mutations in that tumor. UNCeqR was additionally run on the de novo mutation 
identification with default parameters. 
Subclonal analysis. SciClone (Miller et al., 2014) was applied to all related tumors for each 
patient using the mutation calls following computational re-interrogation. The final clone for each 
patient was excluded due to wide scatter across all samples. SciClone was then rerun, and 
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clusters were tested for significance using SigClust (Huang et al., 2015). Clusters that 
overlapped, with the same pattern, and non-significant p values were collapsed into one clone. 
The mean VAF of the mutations comprising each clone was then calculated per tumor. Circles 
were then drawn with the radius of the circle proportionate to the mean VAF. 
R Version. All statistical analyses were performed using R v.3.3.0 in RStudio (RStudio Team, 
2015). 
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Results 
Patient Characteristics 
  To explore the genetic evolution and drivers of breast cancer metastasis, we performed 
DNA whole exome sequencing and RNA sequencing for gene expression on 16 primary 
invasive breast cancers and 67 matched metastases (Figure 3.1, Figure 3.2). Our cohort had a 
median age at diagnosis of breast cancer of 45.5 years old, a median time to relapse of 14.5 
months, and overall survival of 36.5 months (Table 3.1). These patients all received at least 1 
chemotherapeutic agent, and all but one patient received radiation, predominantly to the breast 
and/or brain (Table 3.2). 
  We examined the clinical features and intrinsic molecular subtype of each of the primary 
tumors and their matched metastases. We applied the PAM50 subtype predictor (Parker et al., 
2009) to determine the intrinsic molecular subtype (Appendix 3.1). Breast tumors from 4 
patients were positive for estrogen receptor (ER) expression, but negative for HER2 
amplification (ER+/HER2-) at diagnosis. All four of these patients are luminal or second closest 
to the luminal centroid (due to normal contamination). Primary breast tumors from 3 patients 
were clinically HER2-positive: 1 of the HER2-enriched subtype, 1 of the luminal subtype, and 1 
of the basal-like subtype. Breast tumors from 9 patients were triple negative (negative for ER, 
progesterone receptor (PR), and HER2), with 6 patients classified as the basal-like subtype and 
3 patients second closest to the basal centroid but called as normal-like due to normal tissue 
contamination (Appendix 3.1).  
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Figure 3.1. Experimental design. (A) 16 patients with primary breast cancers and matched 
metastases. (B) DNA Whole exome sequencing and RNA sequencing was performed on all 
tumors. (C) Gene expression, mutations and copy number alterations for all tumors were 
determined for each patient, and each tumor specimen. Subclonality analysis was performed 
with SciClone to define clones, then SigClust to perform posterior significance testing on the 
subclones, and hierarchical clustering to depict relationship of subclones and tumors in each 
patient. DawnRank driver analysis evaluated the network impact of copy number alterations and 
mutations to identify individual drivers in each tumor specimen. 
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Figure 3.2. Distribution of tumor specimens for each patient. Diagrammatic view of the 
tumors from the 16 patients in the UNC Rapid Autopsy Program (RAP) that were sequenced 
with both RNA and DNA whole exome sequencing by site of disease (black = sequenced). 
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Table 3.1. Clinical History for each patient. 
 
  
Patient Race
ER Status (0 
= negative; 
1 = positive)
PR Status (0 
= negative; 
1 = positive)
HER2 Status (0 
= negative; 1 = 
positive)
Age at 
Diagnosis
Stage at 
Diagnosi
s
Time to 
relapse 
(months)
Overall 
Survival 
(months)
A1 Caucasian 0 0 0 64 T4N2M1 0 1.5
A2 African American 1 0 0 57 T3N1M1 0 12
A4 Caucasian 1 1 1 42 T4N2M1 0 22
A5 African American 0 0 0 65 T4N0M0 23 26
A7 African American 0 0 0 57 T2N2M0 17 24
A8 Caucasian 1 1 1 45 T1N1M1 0 48
A11 Caucasian 0 0 0 46 T2N0M0 35 56
A12 Caucasian 1 1 0 64 T3N2MX 9 61
A15 Caucasian 0 0 0 59 T4N0M0 8 12
A17 Caucasian 0 0 0 74 T2N3M0 63 72
A20 Caucasian 0 0 0 63 T2N2M0 22 38
A23 Caucasian 0 0 0 49 T4N2M0 17 37
A26 Caucasian 0 1 1 66 T4N0M0 12 14
A28 African American 1 1 1 38 T1N1M0 91 121
A30 Caucasian 0 0 0 53 T2N0M0 12 36
A34 Caucasian 1 1 0 30 T2N1M0 36 73
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Table 3.2. Therapeutic interventions received for each patient. 
Pt Chemotherapy Estrogen-
directed 
therapy 
Her2 
directed 
therapy 
Other 
biologics 
A1 taxol     
A2 doxorubicin/cytoxin letrozole, 
alendronate 
   
A4 doxorubicin/cytoxin, paclitaxel, 
gemcitabine 
 trastuzumab
, navelbine 
  
A5 docetaxel, 5-fluorouracil, epirubicin, 
cyclophosphamide, capecitabine 
  pamidronate 
A7 doxorubicin/cytoxin,  paclitaxel, 
capectiabine, carboplatin 
    
A8 doxorubicin/cytoxin,  paclitaxel, 
capecitabine 
letrozole, 
fulvestrant 
trastuzumab 
lapatinib 
  
A11 doxorubicin/cytoxin,  paclitaxel, 
gemcitabine, carboplatin 
  Ispinesib 
A12 doxorubicin/cytoxin, paclitaxel, 
capecitabine, vinorelbine,  
gemcitabine, carboplatin, irinotican 
tamoxifen, 
letrozole, 
exemestane, 
fulvestrant 
 bevacizumab 
A15 doxorubicin/cytoxin,  paclitaxel, 
carboplatin, capecitabine, bevacizumab 
 lapatinib cetuximab 
A17 fluorouracil/epirubicin/ 
cyclophosphamide, paclitaxel 
tamoxifen    
A20 doxorubicin/cytoxin, paclitaxel, 
gemcitabine, carboplatin, capecitabine, 
vinorelbine 
  bevacizumab, 
denosumab 
A23 doxorubicin/cytoxin,  paclitaxel, 
carboplatin, capecitabine, gemcitabine 
  bevacizumab, 
anti-death 
receptor 5 
A26 capecitabine, doxorubicin/cytoxin, 
paclitaxel 
tamoxifen, 
letrozole 
trastuzumab   
A28 doxorubicin/cytoxin, paclitaxel, 
gemcitabine, vinorelbine 
tamoxifen, 
letrozole, 
luprolide, 
anastrazole, 
exemestane 
trastuzumab
, TDM1 
samarium, 
denosumab 
A30 gemcitabine, doxorubicin, paclitaxel   denosumab 
A34 doxorubicin/cytoxin,  paclitaxel, 
capecitabine, eribulin, carboplatin, 
gemcitabine 
luprolide, 
tamoxifen, 
letrozole, 
goserelin, 
exemestane 
  bevacizumab, 
denosumab, 
everolimus 
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As reported previously (Harrell et al., 2012), gene expression of tumors from an 
individual patient are highly correlated with one another, regardless of spatial and temporal 
distance from the primary tumor and/or exposure to different therapies (Figure 3.3). This result 
was recapitulated in our sample set: of 16 patients, 4 had all specimens from the same patient 
clustered immediately together, and 14 patients had all tumors contained within the same 
subtype-defining dendrogram branch (Figure 3.3). Two patients, A2 and A4, had primaries of 
the luminal subtype with mixed HER2-enriched and luminal metastases. All of the basal-like 
primaries had metastases of the basal-like subtype.  
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Figure 3.3. Hierarchical clustering of 1098 TCGA Primary breast cancers with the RAP 
primaries and metastases. A. Supervised hierarchical clustering using the PAM50 gene set 
with TCGA and RAP tumors. PAM50 subtype represented and positioning of RAP tumors 
shown in the second row of the color bar. Zoomed in view of the dendrogram of each subtype 
showing the location of tumors from each RAP patient for A. basal-like, B. luminal, and C. 
HER2-enriched sample associated clusters.  
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Computational Re-Interrogations of Mutations in Related Tumors Identifies  
Previous work from our group demonstrated that low frequency clones present at 1-5% 
in the primary tumor are enriched to >40% in the related metastases (Hoadley et al., 2016). 
Other groups have also identified an increased sensitivity and specificity of utilizing genomic 
alignments from multiple related tumors in the whole exome space to identify low frequency 
mutations (Josephidou et al., 2015). Based on these results, we investigated whether mutations 
called with high confidence in one tumor from an individual were present in other tumors from 
that same patient.  
To first control for false positive calls, all germline variants in the population were 
removed using dbSNP (Landrum et al., 2014) as well as mutations with ≥ 20% variant allele 
frequency (VAF) in at least two normal tissues from unrelated patients. All high-quality somatic 
mutations across tumors within each patient were computationally re-interrogated from the 
original DNA binary alignment map (BAM) files in each tumor from that patient. Quantification of 
the VAF was calculated as the read depth of the variant allele/total counts at that position. For 
example, in Patient A20, 304 mutations identified with high confidence across all 6 specimens 
from that patient were computationally re-interrogated in each tumor from this patient (Figure 
3.4). For all tumors, a median of 58 mutations were additionally identified per tumor (Figure 3.5). 
A median of 28.6% of mutations would have been missed if not for the computational re-
interrogation method.  
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Figure 3.4. Timing with which somatic alterations are acquired. (A) A heatmap of the variant 
allele frequencies for Patient A20 for all somatic mutations identified following computational re-
interrogation. (B) Each genetic alteration is categorized as a founder alteration if present in the 
primary and at least 1 metastasis (gray); metastasis-shared if present in ≥ 2 metastases and not 
the primary (blue); or metastasis-private if present in only 1 tumor from that patient (pink). Total 
counts for each category and relative proportions within that patient are then calculated. (C) 
Representative drawing of when during the development of metastasis each category of 
mutations could have occurred: founder mutations established in the original breast cancer and 
maintained throughout metastasis (gray); metastasis-shared mutations occurring after 
metastasis but along shared branches of the tree (blue); or metastasis-private mutations, 
acquired at the final site of metastasis (pink). (D) Quantification of the proportion of mutations 
within each category described in (C) before and after computational re-interrogation. 
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Figure 3.5. Computational re-interrogation of high quality mutation calls related tumors. (A) 
Mutation load per tumor before (gray) and after (green) computational re-interrogation. (B) 
Proportion of mutations within each patient were categorized as founder, metastasis-shared, or 
metastasis-private before re-interrogation (gray boxes) and following re-interrogation (green 
boxes). 
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It is critical to understand when during the development of metastasis genetic drivers are 
acquired. Therefore, we wanted to determine whether this computational re-interrogation altered 
our main conclusions of when during the metastatic process somatic mutations are acquired. 
We categorized mutations on when they possibly occurred in the metastatic process: (1) in the 
primary setting and thus shared between the primary and all metastases (founder, gray); (2) 
during metastatic spread, thus shared with at least 2 metastases but not measured in the 
primary (metastasis-shared, blue); (3) or at the final site of metastasis and thus not shared with 
any other tumor in the patient (metastasis-private, pink) (Figure 3.4A). The total number of 
mutations per category was counted, and the proportion of mutations in each category was 
calculated with the denominator including all mutations observed in the metastases (Figure 
3.4B).  
In Patient A20, there are clear metastatic specific clones as well as common founder 
mutations. Additionally, private mutations are measured in every tumor from this patient. This 
can be represented by an evolutionary tree rooted in the primary with branches representing 
shared genetic events in the metastases but not shared with other branches (Figure 3.4C). 
Within Patient A20, computational re-interrogation of mutations altered the distribution: 37% of 
the mutations originally classified as private to 17% with re-interrogation and 5% originally 
classified as founder mutations shifting to 40% of mutations with re-interrogation (Figure 3.4D). 
Computational re-interrogation across the entire cohort significantly altered the 
categorization of mutations: with the original mutation calls, 60% of mutations per patient were 
considered as private and 12% as founders (Figure 3.5B, gray boxes) compared to 32% of 
mutations per patient considered as private and 40% as founders following re-interrogation 
(Figure 3.5B, green boxes). 
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Figure 3.6. Timing of genetic alterations and driver acquisition in metastasis. Categorization of 
DNA alterations into founder alterations (established in the primary and observed in at least 1 
metastasis), metastasis-shared (shared between at least 2 metastases but not the primary), or 
in only one metastasis (private) for (A) mutations and (B) copy number alterations (CNAs). The 
analyses in A and B were repeated for DawnRank drivers in (D) mutations and (E) CNAs. (F) 
Total number of DawnRank driver genes altered by mutation. (G) Total DawnRank driver counts 
for each tumor including both CNA (gray) and mutation (black).  
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The shift in the majority of mutations being considered as ‘private’ to being measured in 
the original primary tumor has significant clinical implications: if the majority of somatic 
mutations are already established in the original breast cancer, these could be potentially 
targeted to prevent future metastatic seeding with effective therapies. We demonstrate a critical 
need for re-interrogation of mutations in related samples. In matched tumor sets, ignoring low 
frequency mutations could alter the conclusions of a study.  
 
Evolutionary Progression of Genetic Alterations in Breast Cancer Metastasis 
To understand when during the metastatic process somatic mutations and copy number 
alterations (CNAs) occurred, we categorized all somatic alterations within each patient into the 
previously described categories of founder, metastasis-shared, or metastasis-private. Of these 
categories, the majority of mutations and CNAs in the metastases were shared with at least one 
other tumor (mutations: 40% founder; 28% metastasis-shared; 32% private; and for CNAs: 37% 
founder; 40% metastases-shared; 25% metastasis-private; Figure 3.6A-B). Each tumor had a 
median of 185 genes mutated and 8706 genes copy number altered. Only 3 non-synonymous 
mutated genes were common across the dataset: TP53 (13/16 patients), MT-ATP6 (10/13), and 
TTN (9/13); in contrast, large portions of the genome were commonly amplified or deleted in 
most patients across the dataset. 
Many mutations and copy number alterations are likely passenger alterations without 
functional biologic consequences. We therefore used a novel computational tool called 
DawnRank (Hou and Ma, 2014) that integrates DNA alterations, protein-protein interaction 
network, and the expression of these networks via RNA gene expression data for each 
individual tumor. By evaluating the perturbation of the network through RNA gene expression 
data, DNA alterations can be scored and identified as “genetic drivers” on an individual patient 
level (Hou and Ma, 2014). DawnRank network analysis was applied to each tumor, and genes 
with DawnRank network scores in the top 5% of all genes (of 8710 total genes) were then 
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examined for DNA alteration via somatic mutation and CNA. Genes with copy number alteration 
and/or mutation within this top 5% were considered as “genetic drivers”. 
Using this methodology, genetic drivers were even more likely to be “founder” events 
that were established in the primary breast cancer and maintained throughout metastasis when 
compared to the original mutation spectrum (Figure 3.6D; mutations: median of genetic drivers 
in founders was 56%; metastasis-shared was 11%; metastasis-private was 18%). Genetic 
drivers as a result of CNA were also more likely to be “founder” events than the original 
proportions (Figure 3.6E; median of genetic drivers in founders was 41%; metastasis-shared 
was 41%; metastasis-private was 21%). CNAs again comprised the numerically dominant 
somatic mechanism behind driver genes, with each tumor having on average, 6 mutation-based 
driver alterations (Figure 3.6F; Figure 3.6G, black) as compared to 189 CNA-based driver 
alterations (Figure 3.6G, gray). 
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TP53 Drives Breast Cancer Metastasis 
We next examined common DawnRank drivers and the timing with which these 
alterations were established during the progression of metastasis. All 16 patients in our cohort 
harbored TP53 alterations identified by DawnRank as drivers, with 14/16 present in the primary 
and all metastases. Interestingly, tumors from 13/16 patients’ primary tumors had a TP53 
mutation that was not only in the primary, but in every metastasis from that patient (Figure 
3.7A); tumors from the additional 3 patients had copy number loss of TP53, also identified by 
DawnRank as drivers. TP53 mutations were diverse across the protein and altered protein 
function regardless of subtype: Patient A12’s luminal tumors had a 45 base deletion between 
exons 4/5 incorporating the splice site, patient A8’s HER2-enriched tumors had a premature 
stop codon introduced at Arg306*, and tumors from 9/10 of the basal-like patients had either 
nonsense or deleterious missense mutations (Bouaoun et al., 2016).  
RNASeq validation of the presence of these TP53 mutations utilized UNCeqR 
(Wilkerson et al., 2014) in two ways: re-interrogating known mutations in the RNA BAM file as 
well as de novo discovery of mutations with combined DNA and RNA BAM files. Interestingly, 
re-interrogation UNCeqR identified 3/16 mutations while the de novo caller identified an 
additional 4/16 TP53 mutations. These 7 mutations comprise the missense and non-
synonymous TP53 mutations. 6 additional mutations in TP53 were not observed in the RNA: the 
45 bp deletion in A12, 2 frame shift deletions, 2 splice site deletions, and an in-frame deletion 
previously validated with whole genome sequencing (Hoadley et al., 2016).  
DawnRank driver identification of TP53 in every patient in our dataset coupled with 
RNASeq validation of the expression of most of these mutations provides conclusive evidence 
of TP53 disruption as a critical, early event in the formation of aggressive breast cancer. TP53 is 
the only founding driver disrupted by mutation in our metastatic breast cancer patients.  
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Figure 3.7. Timing and frequency of predicted drivers in primary and metastatic breast cancers. 
(A) DawnRank drivers from somatic mutations in at least 2 patients in the cohort (blue gene = 
only luminal patients; red gene = only basal patients). DawnRank copy number (B) 
amplfications and (C) deletions in 14/16 patients. The most frequent copy number drivers seen 
exclusively in basal-like patients for (D) gains and (E) losses are presented. Each driver is 
annotated with chromosomal cytoband location and characterized per patient as a founder 
alteration (gray), metastasis-shared (blue), or metastasis-private (pink) as described in Figure 2. 
  
 
 
71 
Cohort-Wide and Subtype-Specific Genetic Drivers of Breast Cancer Metastasis 
Beyond TP53, genetic drivers caused by mutation were observed in only 3/16 patients: 
ESR1, PIK3CA, and DMBT1 (Figure 3.7A). All other mutation drivers were identified in only 1 or 
2 patients in the dataset, and many were specifically observed in the basal-like patients (Figure 
3.7A, red font).  
In contrast to the low frequency of common mutational drivers in our dataset, many copy 
number amplifications and deletions were consistently identified as drivers in almost all patients. 
Previously identified common regions of amplification in breast cancer (8q, 5p, and 1q) included 
the DawnRank hits ANGPT1, LYN, SDC2, SHC1, GDNF, and TERT identified as drivers in 
15/16 patients, with 6/10 of these events showing amplification in the primary that was 
maintained in metastases in those patients (Figure 3.7B, gray). Common copy number losses 
included FAS, a critical member of the apoptosis cascade, PIK3R1, the repressive subunit of 
PIK3CA, and AURKB, a central inhibitor of the cell cycle pathway Figure 3.7C). 
In an analysis restricted to the basal-like subset of patients (n=10), we collectively 
identified common copy number amplifications of genes involved in cell cycle genes, specifically 
the G1/S transition including CCNE1, CUL1, CDK5 and chromatin associated-proteins RBBP4 
and HDAC1 (Figure 3.7D). BCAN gain specifically in the basal-like patients has not been 
previously described in breast cancer but has been shown to be highly overexpressed in 
aggressive gliomas via STAT3 signaling (Natesh et al., 2015). Interestingly, concurrent basal-
specific copy number loss of non-canonical STAT signaling and brain-specific genes include 
ADRBK1, ADRA2A, and DUSP1 (Figure 3.7E). Basal-like copy number loss of the DNA 
damage cascade regulator RAD51 was also called as a common basal-specific driver (Figure 
3.7E). 
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Resistance to Aromatase Inhibitor Therapy via ESR1 Mutations is Subtype Dependent 
DawnRank driver analysis identified ESR1 mutations specifically in the metastatic 
samples only in 3 ER-positive, luminal patients (Figure 3.7A). ESR1 mutations in the binding 
pocket of the estrogen receptor have been previously described as effectors of resistance 
mechanisms to estrogen suppression by aromatase inhibitors (AIs) (Li et al., 2013; Miller et al., 
2016). Upon re-examining the medical histories of the patient’s in this dataset, 6 patients had 
ER-positive breast cancer and all had received both a nonsteroidal aromatase inhibitor 
(letrozole) and a steroidal aromatase inhibitor (exemestane). Three of the 6 ER-positive patients 
exhibited ESR1 mutations in the metastases but not the primary, and all were called as drivers 
by DawnRank. Interestingly, the 3 ER-positive patients who had received AIs but did not 
develop ESR1 mutations were not of the luminal molecular subtype: A26 = basal-like; A8 = 
HER2-enriched; A2 = mixed luminal/HER2-enriched. 
Confirmatory testing of ESR1 mutations in these 3 patients’ tumors was performed via 
two orthogonal approaches: expression of the mutant version in the RNA via UNCeqR and 
confirmation of DNA mutations with the highly sensitive Droplet PCR system RainDrop. In 
Patient A34, a T to A mutation at chr6:152419922 was called as a somatic mutation in the 
lymph node metastasis (A34-LN-Met; Figure 3.8A, gray), two liver metastases (data not shown), 
and the pancreatic metastasis upon re-interrogation (A34-Pancreatic-Met; Figure 3.8A). This 
variant was confirmed in the RNASeq BAM file for all metastases from this patient (Figure 3.8B). 
Fluorescence measurement of wild-type (y-axis) versus mutant (x-axis) ESR1 confirmed mutant 
ESR1 in both the A34-LN-Met (Figure 3.8C) and A34-Pancreatic-Met (Figure 3.8D) at VAFs 
extremely comparable to those identified in the DNA.  Droplet PCR validation across all 3 
patients demonstrated a sensitivity down to 0.4% VAF in the DNA when using the re-
interrogation method. 
In addition to Patient A34, Patient A12’s and Patient A28’s metastases also exhibited 
ESR1 mutations that cause constitutive activation of ESR1 in the presence of AI therapy (Li et 
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al., 2013, Miller et al., 2016). In A12, 2 of the 5 metastases contained a p.Tyr537Ser mutation in 
ESR1, which was not observed in the primary. Interestingly, Patient A28 had 1 metastasis with 
the p.Tyr537Asn mutation while the other 3 metastases from this patient exhibited a different 
p.Ser463Pro mutation.  
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Figure 3.8. Resistance to aromatase inhibitor therapy via ESR1 mutations. (A) DNA sequencing 
alignment of Patient A34’s ESR1 mutation: wild-type in the primary, chr6-152419922-A-T 
mutation originally discovered in the lymph node metastasis (A34-LN-Met), and discovered in 
the pancreatic metastasis (A34-Pancreatic-Met) following re-interrogation. (B) RNA Sequencing 
alignment at the same genomic location, confirming the re-interrogated mutation in A34-
Pancreatic-Met. Confirmatory testing with Droplet PCR fluorescence quantified wild-type (y axis) 
versus mutant (x axis) ESR1 in (C) A34-LN-Met and (D) A34-Pancreatic-Met. (D) Comparison of 
the variant allele frequency measured from Droplet PCR (y-axis) versus whole exome 
sequencing (x axis) for three luminal patients who received aromatase inhibitor therapy: Patient 
A12 (green dots), A28 (red dots), and A34 (blue dots). R2 and p value are reported for the 
Spearman correlation of the two methods. 
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Multiclonal Seeding of Metastasis is Present in ER+ and ER- Patients 
The subclonal heterogeneity of primary breast cancer was elegantly demonstrated in 
recent publications (Miller et al., 2016; Yates et al., 2015). Whole genome sequencing of two 
triple-negative, basal-like patients in this dataset also demonstrated multiclonal seeding of 
metastasis (Hoadley et al., 2016). To evaluate the clonal evolution of metastasis, we performed 
subclonality analysis with SciClone (Miller et al., 2014). Posterior significance testing of 
SciClone clusters with SigClust was applied to clusters, wherein the radius of the point plotted 
demonstrates the mean variant allele fraction (VAF) of the mutations in a given cluster. 
Of the 16 patients examined, 13 patients had multiple clones in the primary that 
collectively seeded each distant metastasis (Figure 3.9, Figure 3.10, Figure 3.11A). Patients A8, 
A17, and A30 had only a single clone detected in the primary (Figure 3.11A). Within all patients, 
the metastases were multiclonal, meaning each metastasis had at least two clones present. 
Most patients also had metastasis-shared clones, indicating further evolution after metastasis 
occurred. This could be a result of either one metastasis seeding other metastases, clones that 
arose in a separate part of the primary that were not sequenced, or clones present in the 
primary that simply were below our level of detection with NGS-based methods. 
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Figure 3.9. Clonality plots for each basal-like patient. Clones as determined by SciClone and 
posteriorly tested with SigClust are plotted with the radii of the circle proportional to the mean 
variant allele frequency of the mutations in that clone per each tumor. Total number of mutations 
per clone are demonstrated in the last column, and tumor purity is reported at the bottom of 
each plot for A. A1; B. A15; C. A23; D. A26; E. A7; F. A5; G. A30. 
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Figure 3.10. Clonality plots for luminal and HER2-enriched patients. Clones as deter- mined by 
SciClone and posteriorly tested with SigClust are plotted with the radii of the circle proportional 
to the mean variant allele frequency of the mutations in that clone per each tumor. Total number 
of mutations per clone are demonstrated in the last column, and tumor purity is reported at the 
bottom of each plot for A. A28; B. A12; C. A4; D. A2; E. A8. 
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Figure 3.11. Metastatic seeding patterns. (A) Clones present in the primary and metastases 
(founder) as compared to a clone shared by at least 2 metastases in a given patient (metastatic 
clone), arranged according to molecular subtype. (B-E) Each subclone detected in a patient is 
represented as a separate color along the x axis for each primary and metastasis down the y 
axis. The radius of each circle is proportionate to the mean variant allele frequency of that clone 
in each tumor. Private mutations were excluded in clonality analysis. Tumor purity estimates are 
reported on the bottom row, and the total number of mutations per clone are in the right-most 
column. Multi-clonal seeding patterns are observed in basal-like patients (B) A11, (C) A20, and 
luminal patient (D) A34. Monoclonal patterns are identified in 3 patients including basal-like 
patient (E) A17. 
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Clonality plots for basal-like patients are presented in Figure 3.9 and for the luminal and 
HER2-enriched patients in Figure 3.10, with four interesting cases presented in Figure 3.11B-E. 
With each row indicating a distinct clone and each column representing a different tumor, the 
radius of the circle plotted is proportionate to the mean VAF of the mutations in the clone in 
each tumor. Multiclonal seeding was observed in basal-like patients A11 and A20 (Figure 
3.11B-C), and in luminal patient A34 (Figure 3.11D). In Patient A11, the primary contained four 
founding clones present in all specimens (green, purple, orange, and teal), and a subclone 
(gold) that seeded the brain, liver, and cerebellar metastases. The pink subclone is enriched in 
the lung and rib metastases as compared to the brain, liver, and cerebellar metastases. A 
similar complex subclonal pattern was seen in patient A20, with two subclones predominantly 
present in the left lung metastasis and brain metastasis (gold and green) and two separate 
subclones in the liver, adrenal, and right lung metastases (brown and gray). The primary of A20 
also contained 3 subclones that seeded all metastases (purple, organe, and teal). Patient A34, 
mentioned earlier with ESR1 mutations, had an equally complex subclonal pattern, with 5 
subclones present in the primary and in every metastasis at different variant allele fractions 
identified in individual metastases (Figure 3.11D).  
Patient A17 demonstrates monoclonal seeding, with the dominant clone in the primary 
(teal) further evolving separately in the metastases (Figure 3.11E). This pattern was observed in 
3/16 patients, confirming previous reports of monoclonal seeding in breast cancer (Krøigård et 
al., 2015). Private mutations were observed in almost all tumors across the dataset (but are not 
displayed), indicating continued evolution after metastasis, even within each primary tumor. 
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Discussion 
The molecular mechanisms driving the metastatic process are critical to understand in 
order to better prevent and treat existing metastases. Utilizing the UNC Rapid Autopsy Program 
and next generation sequencing of multiple tumors from 16 breast cancer patients, we 
demonstrated that metastasis is largely a result of multiclonal seeding of breast cancer 
metastases in the majority of cases examined. Moreover, our data illustrates that the majority of 
genetic drivers were established in the primary breast cancer and maintained throughout the 
metastatic process; this was observed in both luminal and basal-like breast cancers. We also 
demonstrate that TP53 is the only mutational driver common across all subtypes of breast 
cancer metastasis, and that the majority of drivers were predominantly altered by virtue of 
somatic copy number alterations. Finally, we provide evidence that computational re-
interrogation of high quality somatic mutations is a requirement when studying related tumors, 
as previously classified private mutations are often, in-fact, shared across tumors often with 
lower coverage. 
Previous work using two patients identified multiclonal seeding as a mechanism in 
breast cancer metastasis with the majority of functional mutations established in the primary and 
maintained throughout metastasis (Hoadley et al., 2016). Here, we build upon this very small 
study and demonstrate, at least for basal-like tumors, that multiclonal seeding is a common 
mechanism of metastasis. In patients where multiclonal seeding occurred, the metastasis 
formation must have occurred via a large mass of cells breaking off from the primary (i.e. large 
enough to contain 2, often 3 subclones), which then travels to the distant site and seeds this 
site. This has significant clinical implications including that if the metastasis seed is a clump of 
cells with distinct subclonal populations, then successful therapy to prevent metastasis that are 
focused on inhibiting individual cell migration/motility may have no effect upon tumors that use 
multiclonal seeding.  
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Historically, point mutations or small intragenic in/dels have been regarded as the driving 
force behind oncogenesis. One of the novel aspects of this work was to utilize a more 
functional-based assessment of genetic drivers, DawnRank, which integrates prior knowledge of 
protein interaction networks with mutations, copy number alteration, and RNA expression data 
to refine our ability to identify drivers for each individual patient. By contrast, DNA-only based 
methods can only identify drivers based upon correlation to previous datasets from which 
population-based enrichments of specific genes were determined. Our novel, functional-based 
genetic driver approach demonstrated that the majority of drivers were the result of copy 
number alteration, which also was suggested from a DNA-only approach (Ciriello Nat Gen 
2014). Finally, our results confirm that copy number alterations are established early in the 
development of breast cancer and maintained throughout the evolution of breast cancer 
metastasis (Krøigård et al., 2015). This is contrast to earlier literature in breast cancer 
metastasis demonstrating that a majority of drivers are private and acquired at the final site of 
metastasis (Brastianos et al., 2015).  
We discovered that computational re-interrogation of high quality mutations in one tumor 
are often at lower coverage in the original primary tumor. Furthermore, when considering 
DawnRank computationally predicted functional drivers, the vast majority of drivers are indeed 
established in the primary. In genomic studies of matched tumors from a single patient, it is 
critical to re-examine the sequencing files to fully characterize the timing with which mutations 
are acquired. Clinically, if most of the drivers of breast cancer metastasis are indeed established 
in early development of breast cancer, more effective therapies could possibly prevent or treat 
existing metastases. 
Strikingly, TP53 mutations were seen repeatedly in both basal-like and luminal breast 
cancers, with the mutation always established in the primary and maintained in every 
metastasis from that patient. Beyond TP53, no other driver mutations were present in more than 
3/16 patients in this dataset. Driver analysis identified ESR1 mutations in patients with luminal 
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subtype breast cancers who received aromatase inhibitors (AIs) in the binding pocket of ESR1, 
consistent with previous reports demonstrating the mechanism of resistance to AIs (Li et al., 
2013; Miller et al., 2016). Interestingly, patients who received aromatase inhibitors for non-
luminal yet clinically ER positive tumors did not demonstrate ESR1 resistance mutations in the 
metastatic setting. This molecular diversity of ER-positive tumors (Ciriello et al., 2013; Gatza et 
al., 2014) may explain differential response of many patients’ metastases to aromatase inhibitor 
therapy. 
Our study had a number of limitations, most notably including the sample size of 16 
patients; this inhibited our ability to identify recurrent somatic mutations common to the 
metastatic setting, although our sample size was large enough to identify the importance of 
TP53 and ESR1.  A larger sample size will also be needed to identify site-specific (i.e. lung or 
brain) differences and adaptations. In addition, with only 2 HER2-enriched patients in our 
analysis, additional patients in this subtype are necessary to confirm clonality of metastasis and 
understand resistance mechanisms that develop in HER2-positive breast cancer. Finally, many 
of the primary breast cancers in this dataset were treated with neo-adjuvant (preoperative) 
therapy prior to mastectomy. Future studies comparing matched therapy-naïve, post-neo-
adjuvant therapy, axillary lymph nodes, liquid biopsies, and distant metastases will be needed to 
understand the earlier steps of clonal evolution.  
In summary, this study validates and further expands upon the compelling evidence of 
multiclonal seeding across multiple subtypes of breast cancer, especially for TNBC/Basal-like 
tumors. Additionally, we demonstrate that most genetic drivers arise from copy number 
alterations. The mechanism to generate genetic diversity is largely unknown; however, the 
consistency across our cohort and previous literature suggests that TP53 dysfunction is an early 
and critical event in the development of aggressive breast cancer. Despite the high degree of 
heterogeneity in primary breast cancer (Yates et al., 2015) maintained through metastasis via 
multiclonal seeding, these results also show that the majority of genetic drivers are established 
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in the primary breast cancer and maintained throughout metastasis. This gives hope that 
therapeutic targeting of the founding events that drive the metastatic phenotype might prevent 
metastatic spread or inhibit the progression in the advanced setting.  
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APPENDIX 3.1: PAM50 Analysis of A16 Tumors 
Sample Name 
Tissue 
Type 
RNASeq 
Method Basal Her2 LumA LumB Normal Call 
A11.PT.FFPE FFPE Ribo0 0.60 0.07 -0.54 0.02 -0.08 Basal 
A17.Primary.FFPE FFPE Ribo0 0.24 
-
0.08 -0.02 -0.23 0.32 Normal 
A2.Primary.FFPE FFPE Ribo0 -0.11 
-
0.17 -0.01 0.27 -0.21 LumB 
A20.Primary.FFPE FFPE Ribo0 0.63 
-
0.38 -0.23 -0.33 0.34 Basal 
A23.Primary.FFPE FFPE Ribo0 0.81 0.01 -0.67 -0.09 -0.08 Basal 
A23.LN.Met.FFPE FFPE Ribo0 0.79 0.09 -0.74 0.05 -0.19 Basal 
A26.Primary.FFPE FFPE Ribo0 0.17 
-
0.54 0.22 -0.25 0.45 Normal 
A28.PT.FFPE FFPE Ribo0 -0.02 
-
0.62 0.52 -0.45 0.66 Normal 
A30.Primary.FFPE FFPE Ribo0 -0.07 
-
0.55 0.59 -0.47 0.75 Normal 
A34.Primary.FFPE FFPE Ribo0 -0.25 
-
0.53 0.67 -0.37 0.68 Normal 
A1.LUNG.MET FF polyA 0.52 
-
0.10 -0.24 -0.51 0.39 Basal 
A1.ADRE.MET2 FF polyA 0.58 
-
0.17 -0.31 -0.37 0.29 Basal 
A1.AX.LN.MET FF polyA 0.58 
-
0.05 -0.35 -0.36 0.25 Basal 
A1.PRIMT.2 FF polyA 0.56 
-
0.09 -0.29 -0.43 0.31 Basal 
A1.LIV.MET2 FF polyA 0.62 
-
0.12 -0.37 -0.35 0.25 Basal 
A1.SPIN.MET1 FF polyA 0.69 
-
0.13 -0.47 -0.33 0.21 Basal 
A11.BRAIN.MET FF polyA 0.57 0.03 -0.48 -0.19 0.00 Basal 
A11.LUNG.MET FF polyA 0.56 0.08 -0.52 -0.10 -0.07 Basal 
A12.LIV.MET FF polyA -0.39 0.10 0.10 0.30 -0.15 LumB 
A12.SkullMet FF polyA -0.17 
-
0.20 0.08 0.23 -0.13 LumB 
A12.AdrenalG.Met FF polyA -0.39 
-
0.24 0.49 0.03 0.27 LumA 
A12.PleuraMet FF polyA -0.36 
-
0.08 0.24 0.18 0.07 LumA 
A12.LN.Met.subcarinal FF polyA -0.13 0.04 -0.02 0.11 -0.06 LumB 
A12.RLL.MET FF polyA -0.28 
-
0.22 0.28 0.02 0.22 LumA 
A12.PRIMT020076B FF polyA -0.64 
-
0.05 0.53 0.10 0.03 LumA 
A15.LiverMet FF polyA 0.54 
-
0.11 -0.28 -0.43 0.33 Basal 
A15.ChestWallMet FF polyA 0.41 
-
0.04 -0.15 -0.44 0.40 Basal 
A15.PRIMT070427B FF polyA 0.61 
-
0.12 -0.44 -0.27 0.14 Basal 
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A15.LN.MET FF polyA 0.55 
-
0.14 -0.35 -0.30 0.19 Basal 
A15.MediastnMet FF polyA 0.42 
-
0.06 -0.14 -0.45 0.41 Basal 
A17.3.LivMet.1 FF polyA 0.55 0.07 -0.40 -0.33 0.25 Basal 
A17.9.ChestMet FF polyA 0.53 0.09 -0.41 -0.36 0.28 Basal 
A2.LungMet FF polyA -0.27 0.21 0.08 0.04 -0.01 Her2 
A2.LN.Met.Subcarinal FF polyA -0.25 0.12 0.13 -0.02 0.06 LumA 
A20.BrainMet FF polyA 0.67 
-
0.26 -0.33 -0.45 0.33 Basal 
A20.AdrenalMet FF polyA 0.69 
-
0.21 -0.43 -0.36 0.25 Basal 
A20.LungMet.L FF polyA 0.67 
-
0.22 -0.32 -0.48 0.39 Basal 
A20.LivMet FF polyA 0.67 
-
0.08 -0.53 -0.26 0.16 Basal 
A20.LungMet.R FF polyA 0.68 
-
0.18 -0.41 -0.41 0.31 Basal 
A23.BrainMet.3 FF polyA 0.67 
-
0.09 -0.38 -0.44 0.27 Basal 
A23.PleuraMet FF polyA 0.62 0.00 -0.41 -0.31 0.23 Basal 
A23.BrainMet.2 FF polyA 0.67 
-
0.08 -0.40 -0.38 0.24 Basal 
A23.BrainMet FF polyA 0.63 
-
0.11 -0.35 -0.46 0.28 Basal 
A26.Lung.Met.2 FF polyA 0.57 
-
0.06 -0.47 -0.17 0.04 Basal 
A26.Lung.Met.1 FF polyA 0.39 
-
0.06 -0.46 -0.09 -0.02 Basal 
A26.SoftTissueMet FF polyA 0.39 0.11 -0.50 -0.08 -0.17 Basal 
A28.LungMet.LLL FF polyA -0.42 0.10 0.29 0.25 -0.10 LumA 
A28.LivMet.1 FF polyA -0.54 
-
0.10 0.49 0.20 0.04 LumA 
A28.LungMet.RUL FF polyA -0.49 
-
0.15 0.48 0.14 0.07 LumA 
A28.AdrenalMet FF polyA -0.26 
-
0.01 0.15 0.22 -0.06 LumB 
A28.PancreasMet FF polyA -0.49 
-
0.16 0.48 0.11 0.12 LumA 
A28.DuraMaterMet FF polyA -0.19 0.01 0.11 0.20 -0.05 LumB 
A30.LivMet.R FF polyA 0.69 0.12 -0.46 -0.33 0.17 Basal 
A30.LivMet.L FF polyA 0.75 0.11 -0.53 -0.33 0.11 Basal 
A30.BrainMet.L4 FF polyA 0.69 
-
0.09 -0.32 -0.54 0.29 Basal 
A30.BrainMet.Occi FF polyA 0.70 
-
0.11 -0.43 -0.32 0.15 Basal 
A30.BrainMet.R FF polyA 0.76 
-
0.09 -0.42 -0.42 0.18 Basal 
A34.PancreasMet FF polyA -0.42 
-
0.28 0.61 -0.14 0.41 LumA 
A34.LiverMet.L FF polyA -0.65 
-
0.11 0.61 0.14 0.13 LumA 
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A34.LN.Met FF polyA -0.56 
-
0.11 0.51 0.18 0.06 LumA 
A34.LiverMet.R FF polyA -0.57 
-
0.19 0.63 -0.02 0.22 LumA 
A4.LLL.MET FF polyA 0.11 0.42 -0.26 -0.09 -0.10 Her2 
A4.PRIMT020306B FF polyA -0.18 
-
0.39 0.50 -0.31 0.44 LumA 
A4.LUL.MET FF polyA -0.21 
-
0.05 0.46 -0.46 0.50 Normal 
A5.SKIN.Met.L FF polyA 0.69 
-
0.10 -0.49 -0.22 0.13 Basal 
A5.SKIN.Met.R FF polyA 0.61 
-
0.13 -0.40 -0.29 0.24 Basal 
A5.PRIMT030065B FF polyA 0.71 
-
0.17 -0.49 -0.19 0.10 Basal 
A7.RIB.MET FF polyA 0.75 
-
0.06 -0.41 -0.41 0.20 Basal 
A7.LUNG.MET1 FF polyA 0.70 
-
0.15 -0.33 -0.47 0.35 Basal 
A7.LIV.MET1 FF polyA 0.74 0.01 -0.54 -0.29 0.15 Basal 
A7.PRIMT020552B FF polyA 0.78 
-
0.28 -0.36 -0.54 0.43 Basal 
A7.KIDNYMET FF polyA 0.56 
-
0.06 -0.23 -0.46 0.37 Basal 
A8.LUNG.MET FF polyA -0.16 0.50 -0.25 0.16 -0.29 Her2 
A8.030222BSPIMET FF polyA -0.39 0.40 0.08 0.22 -0.18 Her2 
A8.LIV.MET FF polyA 0.00 0.49 -0.34 0.26 -0.32 Her2 
A8.OVA.MET FF polyA -0.20 0.19 0.09 -0.13 0.16 Her2 
A8.SPIN.MET FF polyA -0.12 0.11 0.13 -0.27 0.25 Normal 
A11.RIB.MET FF Ribo0 0.58 0.08 -0.50 -0.26 0.07 Basal 
A11.CELEB.MET FF Ribo0 0.56 0.03 -0.44 -0.27 0.12 Basal 
A11.LIV.MET FF Ribo0 0.60 0.03 -0.51 -0.22 0.03 Basal 
A15.LUNG.MET FF Ribo0 0.40 
-
0.25 -0.03 -0.65 0.54 Normal 
A2.LivMet FF Ribo0 0.10 0.00 0.01 -0.35 0.23 Normal 
A7.BRAIN.Met FF Ribo0 0.68 
-
0.15 -0.26 -0.57 0.42 Basal 
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CHAPTER 4 – INTEGRATED MUTATIONS AND COPY NUMBER COMPUTATIONAL DRIVER 
CLASSIFICATION IDENTIFIES NOVEL AND KNOWN SUBTYPES OF BREAST CANCER 
Preface 
 This manuscript is a shared first co-authorship between Jack Hou and myself. Grace 
Silva curated the TCGA and METABRIC copy number data. Jack Hou created the DawnRank 
method with Jian Ma, identified the subgroups, and performed the ClaNC classification. The 
classification was edited by myself and Dr. Charles Perou. I performed all subsequent analyses. 
Dr. Perou conceived this project. 
 
Introduction 
Breast cancer remains the second leading cause of cancer related death in women each 
year. Breast cancer is a heterogeneous disease with distinct molecular and clinical subgroups 
(Perou et al., 2000); however, even patients within the same molecular subgroup can have 
highly variable first sites of metastasis and differential response to targeted therapeutics(Carey 
et al., 2006; Ciriello et al., 2013). Identification of the underlying drivers of breast cancer could 
help identify the molecular cause of this heterogeneity while concurrently providing novel 
therapeutic targets.  
Large efforts to identify the genetic underpinnings causing breast cancer have led to 
unprecedented amounts of both DNA and RNA genomic data (Cancer Genome Atlas, 2012; 
Ciriello et al., 2015; Curtis et al., 2012). Genomic instability is a hallmark of cancer, leading to 
many mutations and copy number alterations per tumor; however, the significance of these 
alterations often is not well understood. Previous efforts to identify drivers rely heavily on 
mutation data, defining drives as those genes with mutations above the background rate of 
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mutation (Dees et al., 2012b; Forbes et al., 2015; Lawrence et al., 2013). Copy number 
alteration (CNA), however, is known to be an early, common, and critical factor in the 
development of breast cancer (Cancer Genome Atlas, 2012; Hoadley et al., 2016; Krøigård et 
al., 2015). Additionally, CNAs alter large numbers of genes in the same area of the genome, 
making it difficult to identify the actual driver in an area of alteration. Genetic driver analyses 
incorporating both mutation and CNAs provide a novel method of defining breast cancer drivers. 
Integration of RNA gene expression network analyses can accurately reflect oncogenic 
pathway alteration. DawnRank (Hou and Ma, 2014) allows for the integration of RNA gene 
expression, DNA mutations, and DNA copy number data. The proportion of drivers from CNA as 
compared to mutation is not well known. Additionally, it is not well known if drivers on an 
individual tumor level are consistent within and across subtypes or private to a tumor. A better 
understanding of the biology driving breast cancer needs to be explored with the hopes of 
identifying novel, tractable therapeutic targets. 
In this analysis, we have applied the novel computational method DawnRank (Hou and 
Ma, 2014), which predicts potential driver genes in individual samples, to the Cancer Genome 
Atlas breast cancer freeze set (Ciriello et al., 2015) followed by ConsensusClusterPlus 
(Wilkerson and Hayes, 2010) to identify novel subgroups. A ClaNC classifier (Dabney, 2006) 
was then identified, and the classifier applied to METABRIC (Curtis et al., 2012; Pereira et al., 
2016) for validation. Finally, we characterize the molecular and clinical phenotypes of each 
subgroup with additional analyses of publicly available clinical data, RNA gene expression 
signatures, protein expression, and survival outcomes.  
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Methods 
Patient sample selection 
We selected tumors with gene expression, mutation, and copy number data from The 
Cancer Genome Atlas (TCGA) breast cancer dataset (n = 871) and the Molecular Taxonomy of 
Breast Cancer International Consortium (METABRIC) dataset (n = 1,992). We randomly 
selected 500 samples from each dataset, keeping relative distribution of PAM50 subtypes 
consistent between the two datasets. The composition of samples is 19.3% Basal, 10.9% Her2, 
39.5% Luminal A, and 30.3% Luminal B. Normal-like breast cancers are not included in this 
analysis.  
DawnRank score calculation 
To assess a mutation or copy number alteration’s impact on the differential gene 
expression of downstream genes in the network, DawnRank (Hou and Ma, 2014) was applied. 
Briefly, gene networks were built from both curated and non-curated human gene interactions 
obtained from the MEMo paper (Ciriello et al., 2012) and KEGG analyses (Kanehisa et al., 
2012). DawnRank’s default dynamic damping factor parameter μ was 3, and the default 
Condorcet penalty parameter 𝛿 0.85. Gene expression data was first converted into a Z-score. 
DawnRank scores were next calculated according to the previously published method, such that 
the rank reflects their driver potential in a given sample. A non-parametric score based on the 
rank-order of DawnRank genes in each sample was used due to the uncertainty that individual 
DawnRank scores followed a distribution (QQ correlation 0.569).  
For each patient, segmented CNAs were converted into a discrete copy number gene 
matrix, with significant segment means greater than .1 assigned to 1 and means less than -.1 
assigned to -1. Using the hg19 gene annotation, genes that were completely encompassed 
within a segment based on genomic location were assigned that segment's discrete copy 
number value. For mutations, a mutation in known tumor suppressors were assigned -1 while 
mutations in known oncogenes are assigned 1 (Schroeder et al., 2014). If no mutation or copy 
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number alteration is present, the gene has a score of 0. DawnRank scores were converted into 
a rank-based percentage and then multiplied by both the mutation and copy number alteration 
matrices. Thus, DawnRank scores ranged from -100 (copy number loss/tumor suppressor 
mutation) to 100 (copy number gain/oncogene mutation). Only tumors with at least 5 non-zero 
DawnRank genes were further considered. 
Cohort level DawnRank scores were also calculated using a modified Condorcet voting 
scheme to assess the population-level driver potential of a given gene, as previously described 
(Hou and Ma, 2014). A p-value was calculated by fitting a normal distribution over the cohort-
level scores. Only genes with a cohort-wide p-value < 0.05 were considered for subtype 
classification.  
Alteration based subtype classification using consensus clustering 
TCGA DawnRank scores were clustered using  ConsensusClusterPlus (Wilkerson and 
Hayes, 2010), testing k =2 to k = 10 with 1,000 iterations and 80% sampling. Sample distances 
were calculated using the Pearson distance over 1,000 iterations. k  = 5 was selected as the 
maximum number of groups with the minimal number of misclassifications. 
Validation classifier 
To define a robust classifier, we employed ClaNC (Dabney, 2006). ClaNC ranks features 
based on t-statistics and then employs a custom Linear Discriminant Analysis to define 
centroids for each group. TCGA DawnRank drivers were tested with ClaNC beginning with 10 
features and increasing by 5 features with the default parameters. Performance of the ClaNC 
classifier was defined by comparing misclassification rate of TCGA tumors with the ClaNC 
classifier to ConsensusClusterPlus group identity.  
 
Statistical analyses  
Gene Expression Signatures. 420 previously published signatures were curated from multiple 
sources (Bindea et al., 2013; Fan et al., 2011; Gatza et al., 2010; Hoadley et al., 2007; Hu et al., 
 
 
91 
2009; Iglesia et al., 2014). For each signature, the mean of the genes comprising that signature 
was calculated for each tumor including TCGA normal breast samples, the 1098 freeze lobular 
dataset(Ciriello et al., 2015), and METABRIC tumors.  
Subtype-defining expressed features. To define subtype-specific features, significance 
analysis of microarray (Tusher et al., 2001) was applied in two ways: first, multiSam (an ANOVA 
permutated 100 times) compared variation across all subgroups; secondly, each subgroup was 
compared to all others in a two-class, unpaired parametric t-test again permutated 100 times. 
Features were considered significant if both the false discovery rate from the multiSam and at 
least one of the two-class comparisons were 0.  
Survival analyses. Overall survival data was calculated up to 10 years and plotted using a 
Kaplan-Meier survival curve using the survival package in R. Patient samples with greater than 
10 year survival are censored at the 10-year mark. Log-ranked likelihood test was used to 
compare significance among subgroups.   
R Version. All statistical analyses were performed in R v.3.3.2 . 
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Results 
Identification of driver-based subtypes 
In order to define the genetic drivers of breast cancer through an integrated analysis of 
gene expression, copy number, and mutation, we first applied DawnRank to the TCGA breast 
cancer dataset (Figure 4.1). Genes with cohort-wide DawnRank p values <= .05 were 
considered for clustering to define driver-subtypes. 65 copy number altered genes and 38 
mutated genes were significant across the cohort (Figure 4.2A).  
ConsensusClusterPlus was applied to the tumors with at least 5 features identified 
utilizing 1000 iterations and 80% resampling of genes and samples. Varying the number of 
groups from k  = 2 to k = 10, we identified five as the ideal number of clusters by observing the 
maximum cophenetic correlation (Figure 4.2A, color bar). We compared the clusters after 25 
different runs of ConsensusClusterPlus and observed consistent clustering results with a 
pairwise Rand Index of 0.97. Silhouette widths were calculated as the distance to the centroid, 
and samples were ordered accordingly.  
To define a robust predictor of driver subtype, we evaluated the ClaNC classifier using 
these 113 features. A t-test of each feature in one subgroup compared across the subgroups 
was calculated to obtain subtype-defining features (Figure 4.2B). The only mutations in the first 
50 features were PIK3CA, TP53, CDKN1B, and CDH1. This highlights copy number alterations 
as a critical mechanism driving breast cancer biology. Using the ConsensusClusterPlus 
subgroups to compare, we increased the number of features in the classifier by 5 and tested the 
performance of the ClaNC classifier (Figure 4.3). Misclassification rates varied by subtype 
(Figure 4.3), with the CN0 subtype (solid black line) having the highest misclassification rate. 73 
features were selected to build the centroid for each subtype, with 61 copy number alterations 
and 12 mutations.  
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Figure 4.1. Overview of Method. A schematic diagram detailing the selection of tumor samples 
from TCGA and METABRIC, calculation of DawnRank scores, clustering to define subgroups, 
building the classifier using ClaNC, and finally applying this classifier to the validation dataset 
with METABRIC tumors. 
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Figure 4.2. DawnRank Subtype Identification. (A) DawnRank scores were calculated (red = high score, 
oncogene; green = high score, tumor suppressor), and clusters identified using ConsensusClusterPlus. 
Tumors are ordered by the distance to the centroid. Copy number alterations and mutations are ordered 
by chromosome and position in the genome. (B) T statistics are plotted for each group, calculated by 
comparing one group to all other tumors (red = maximum association; blue = negative association). (C) 
Molecular and clinical characteristics of each tumor with Chi square test p values reported (black = 
positive or mutated; white = negative or wild-type).  
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Figure 4.3. Misclassification Rate of ClaNC. Increasing features by 5, misclassification rate was 
calculated by comparing ClaNC classifier to the original ConsensusClusterPlus subgroup 
identification (blue = DR-LumA/B; red = DR-Basal, green = DR-Immune; black solid = DR-DR-
CN0; purple = DR-LumA; black dashed = overall rate). Vertical line indicates the chosen number 
of features in the final classifier. 
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Subtype-defining drivers 
To define subtype-specific drivers, each driver (68 CNAs and 38 mutations) was tested 
by t statistic with one class against all others (Figure 4.4B). DR-LumA/B is defined by chr11q loss 
including BIRC3, ATM, CBL, and the T cell receptor family genes CD3E/D/G. Examination of 
the BIRC3 DawnRank network demonstrates a distinct up-regulation of PAK1, a known 
oncogene that activates MAPK and MET signaling (Figure 4.5) (Shrestha et al., 2012). This 
network may be the cause of the increased proliferation rate of DR-LumA/B compared to other 
ER-positive tumors.  
Interestingly, the Immune subgroup lacks 1q amplification but has distinct gain of 8q 
amplification. ERBB2 is located at 8q, but other drivers defined here include IKBKB, LYN, 
COPS5, NCOA2, and SDC2. LYN is a known oncogene that can mediate anti-estrogen 
resistance in ER-positive breast cancer (Schwarz et al., 2014). In contrast, the DR-Basal 
subgroup has 1q amplification and a lack of focal 16p13.3 amplification and 8q amplification.   
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Figure 4.4. DawnRank scores and statistics of ClaNC features. DawnRank scores of the 75 features 
selected in the ClaNC classifier, with tumors ordered by subgroup and the distance to the centroid and 
features ordered first by copy number alteration or mutation and secondly by genomic location. T statistic 
is reported as the t-estimate for each subgroup compared to all other tumors. 
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Figure 4.5. BIRC3 network distinctly altered in DR-LumA/B tumors. (A) A network view in the 
DR-LumA/B subtype detailing the gene interactions between BIRC3 and nearby genes in the 
network up to two levels downstream. Red nodes represent down-regulation and green nodes 
represent overexpression. The intensity of the node represents the magnitude of gene 
expression. Edge thickness and color represent the distance between these gene in question 
and BIRC3. Magenta edges represent 1 degree of separation from BIRC3, black represents 2, 
and gray represents 3. (B) A network view of BIRC3 in non-Luminal subtypes. 
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Clinical and Molecular Heterogeneity within the Driver Subgroups 
To classify the driver-subtypes in context of previously defined clinical predictors and 
molecular taxonomy, we examined the correlation with PAM50 subtype, known clinical 
predictors, and IntClust. Predominantly tumors of the PAM50 Luminal B subtype comprise the 
first subgroup, defined by ER and PR positivity as well as an increased proliferation rate (Figure 
4.2C). Two luminal A subtypes were identified, one with a distinct lack of 1q amplification thus 
called copy number neutral (CN0). This subset of luminal A breast cancers have been 
previously reported both in a subset analysis of TCGA luminals (Ciriello et al., 2013) and 
defined in the METABRIC IntClust taxonomy(Curtis et al., 2012).  
Interestingly, two subgroups are comprised of a mixture of basal-like, HER2-enriched, 
and Luminal B tumors. These tumors have significantly increased proliferation rates, higher 
rates of TP53 mutation, and lack ER and PR expression (Figure 4.2C). This is the first classifier, 
to our knowledge, to categorize PAM50 basal-like and HER2E tumors into two subgroups.  
Clinically, tumor stage (T) and nodal status (N) do not correlate with the driver subtype 
classification (Figure 4.2C). This demonstrates the added knowledge of these subtypes above 
known clinical characteristics.  
Protein and Pathway Expression Varies by Driver Subgroup 
To identify pathways differentially expressed, we performed parametric t-tests and 
ANOVA testing of each class versus all others to identify protein and gene expression 
differences among the subgroups. Utilizing previously published gene signatures, the mean 
gene signature scores for each tumor were compared. Interestingly, the luminal progenitor 
signatures were highly expressed in the DR-Basal subgroup with concurrent down-regulation of 
mature luminal and estrogen signaling gene expression signatures (Figure 4.6A). Not 
surprisingly, those subgroups dominated by ER-negative tumors had lower expression of 
estrogen markers; however, even the PAM50-Luminal B tumors that were grouped into the DR-
Basal subgroup  
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Figure 4.6. RNA Pathway signatures and protein alterations. Signatures and protein expression 
significant across the cohort by a parametric ANOVA and also significant in at least one 
subgroup compared to all others (FDR = 0) were median centered across the cohort and 
clustered. Tumors were ordered by the distance to the centroid within each subgroup. 
 
 
101 
 
Figure 4.7. PAM50-Luminal B tumors reclassified into DawnRank subgroups. (A) DawnRank 
scores for the n=98 PAM50-Luminal B tumors demonstrate DR-subtype defining features. (B) T 
statistics are reported as each subtype compared to all other tumors.  
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Figure 4.8. Gene expression signature differences. Boxplots demonstrating variability of gene 
sigantures and protein expression both across all TCGA samples as well as those specifically 
characterized by the PAM50 classifier as Luminal B for the Mature Luminal signature (A,B), B 
cell signature (C,D), and ERa protein expression (E,F). 
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have lower expression of the mature luminal and estrogen signaling pathways. This indicates an 
alteration in estrogen signaling in these tumors concurrent with an increased proliferation. 
The other group of signatures significantly expressed are the immune signatures. 
Significant up-regulation of the immune gene signatures define the Immune subgroup. Again, 
PAM50-Luminal B tumors that were classified into the Immune DawnRank subtype have 
significantly higher immune infiltrate than those in the DR-LumA/B subgroup (Figure 4.8A).  
In addition to the gene expression signatures, we also analyzed publicly-available 
reverse phase protein arrays (RPPA) data from the Cancer Genome Atlas to investigate protein 
expression differences. Known estrogen signaling proteins including GATA3, INPP4B, and AR 
are overexpressed in the more luminal subtypes, DR-LumA/B, DR-Luminal A, and CN0 (Figure 
4.6B). This confirms protein expression of the gene expression measured in Figure 4.6A: 
distinct down-regulation of estrogen signals in ER-positive tumors are classified by our 
DawnRank classifier.  
 
DawnRank Subtypes Confer Improved Survival Differences Beyond Current Clinical and 
Molecular Predictors 
Utilizing gene expression, recently published mutation data (Pereira et al., 2016), and 
copy number data from the METABRIC dataset (n = 339 patients), we calculated the DawnRank 
scores for each tumor and applied the ClaNC classifier. METABRIC confirms the association of 
the DawnRank subtypes with the PAM50 classifier. We further confirmed the gene expression 
signature associations with subtype as analyzed above, validating the increased immune 
expression in the Immune subgroup and loss of differentiation in ER-positive tumors of the DR-
Basal subtype Figure 4.10. To first examine the differences in survival prediction, we performed 
Kaplan-Meier plots and survival analysis of the DawnRank subtypes and PAM50 classifier. 
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Figure 4.9. Validation of expression differences with METABRIC. Gene signature scores for the 
Mature Luminal signature (A,B), and B cell signature (C,D) both across all of TCGA and only in 
the PAM50 Luminal B subtype. 
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Figure 4.10. Association of survival by subtype. Kaplan-Meier plots and log rank tests of the 
overall survival up to 10 years from the METABRIC dataset of three classifiers: (A) DawnRank, 
(B) PAM50, and (C) IntClust classifiers. 
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While DawnRank is not significant by log likelihood test, PAM50 demonstrate significant 
separation of subtypes (Figure 4.9). We next tested univariate and multivariate Cox proportional 
hazard comparing survival and clinical or molecular variables. When incorporating DawnRank 
subtype in addition to the clinical variable, DawnRank subtype contributed survival outcome 
information in addition to ER status, PAM50 subtype, IntClust classification, TP53 mutation 
status, nodal status, ERBB2 status, and tumor size. Interestingly, ERBB2 status and IntClust 
subtype were not significantly predictive of survival alone.  
We then tested DawnRank subtype in a multivariate Cox proportional hazard test, 
incorporating ER status, Stage, nodal status, PAM50-subtype, and DawnRank (Table 4.1). 
Nodal Status had the most significant prediction power, followed by DR-LumA/B and Immune 
subtypes. PAM50-Basal and DR-LumA were also significant. Interestingly, ER status was not 
significant. 
In this study, we have demonstrated the ability to use an indirect classifier of empirical 
driver analyses to generate robust subgroups associated with both clinically relevant features as 
well as clinical outcome. 
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Table 4.1. Cox proportional hazard test of DawnRank subgroups with other known molecular 
and clinical features. 
 coef exp(coef) se(coef) z Pr(>|z|) Significance 
ER status (positive) -0.768 0.464 0.457 -1.680 0.093 . 
Stage1 -0.334 0.716 0.357 -0.936 0.349  
Stage2 -0.265 0.767 0.257 -1.029 0.303  
Stage3 0.301 1.352 0.415 0.727 0.467  
PAM50-LumB 0.493 1.637 0.266 1.851 0.064 . 
PAM50-Her2 0.463 1.589 0.462 1.002 0.316  
PAM50-Basal 1.008 2.740 0.516 1.953 0.051 . 
Nodal status 0.558 1.746 0.169 3.308 0.001 *** 
DR-LumA 0.968 2.632 0.476 2.031 0.042 * 
DR-LumA/B 1.208 3.346 0.436 2.770 0.006 ** 
DR-Immune 0.995 2.705 0.387 2.573 0.010 * 
DR-CN0 0.694 2.001 0.438 1.583 0.113  
---       
Significance. codes: 0 ‘***’ 0.001 ‘**’ 0.01 ‘*’ 0.05 ‘.’ 0.1 ‘ ’ 1 
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Discussion 
We present a novel classification of breast cancer by calculating heuristic driver scores 
from and integration of gene expression, copy number, and mutation data. Utilizing both The 
Cancer Genome Atlas (TCGA) as a test set and the Molecular Taxonomy of Breast Cancer 
International Consortium (METABRIC) as the validation set, we demonstrate five robust driver-
subtypes. Our subtypes include a pure Luminal A subtype, a copy number neutral subtype, a 
pure Luminal B subtype, and two mixed subtypes: one with an increase in immune infiltration 
and the other demonstrating a de-differentiation phenotype. 
Known hotspots of copy number alteration in breast cancer, including 1q amplification, 
8q amplification, 11q loss, and 16q loss, demonstrate subtype-specific differences. 
Chromosome 11 loss is specific to the DR-LumA/B subtype including BIRC3 and CBL loss. 
BIRC3 network analysis demonstrates loss of BIRC3 and concurrent up-regulation of PAK1, a 
known oncogene downstream of BIRC3. A second interesting result is the loss of CBL, an E3 
ubiquitin protein ligase which recognizes known oncogenes including FGFR2, KIT, and 
PDGFRA. CBL loss has not been previously described in the context of Luminal breast cancer. 
Targeting of FGFR family members with dovitinb has been showing to be effective in a small 
cohort of breast cancer patients in Phase 2 trial (André et al., 2013). CBL loss could be a 
second marker for FGFR sensitivity in patients who lack FGFR amplification but still may be 
dependent on this pathway.  
Integrating gene expression to evaluate the impact of a genomic alteration, both 
mutation and copy number alterations, allows for novel subgroup identification. We demonstrate 
that these subgroups have survival differences beyond known clinical and molecular markers. 
There is information to be gained by utilizing a dynamic, integrated driver analysis including 
identification of novel therapeutic targets such as PAK1 in DR-LumA/B tumors. Improving our 
understanding of the molecular drivers of underpinning different subtypes of breast cancer are 
necessary to develop more targeted therapies.  
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Future in vitro and in vivo confirmation will be needed to confirm our findings. In addition, 
we are limited by known, curated pathways used to evaluate the networks. Assessment of these 
drivers through both therapeutic selection (comparing pre-treatment and post-treatment 
samples) and the selection of these drivers through the metastatic process are needed. 
DawnRank network-based analysis on both metastases and clinical trial samples with available 
gene expression, mutation, and copy number data are needed to understand the shift in drivers 
during these selection processes. 
The heterogeneity of breast cancer has long been described and understood from a 
clinical, histopathologic, and molecular lens. Through a novel computational framework, we 
were able to capture this heterogeneity and assess novel molecular drivers for each breast 
cancer subtype. Future functional studies confirming the role of these drivers in a subtype-
specific manner are needed in order to lead to novel therapeutic development. Incorporation of 
mutations, copy number alterations, and gene expression confirm the importance of evaluating 
not only mutations but also copy number variations in understanding the underlying biology 
driving breast cancer.  
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CHAPTER 5 – DISCUSSION AND CONCLUSION 
Breast cancer metastasis is still a devastating diagnosis with limited treatment options, 
especially for women with hormone receptor negative breast cancer. A better understanding of 
the process of metastasis, the timing with which the metastatic potential is established, and the 
common drivers in metastasis are needed to develop better therapeutic interventions. By 
comparing matched primary breast cancers and multiple metastatic sites, we described the 
clonal process of evolution in 16 patients, defined computationally-determined drivers, and 
identified the timing with which these drivers were acquired. Through these research projects, 
we attempted to clarify three questions: (1) is metastasis a monoclonal or polyclonal event; (2) 
when are metastatic drivers acquired; (3) what are common mechanisms of metastasis. 
 
Polyclonal Seeding in Breast Cancer Metastasis 
We determined that polyclonal seeding can occur in both luminal and basal-like breast 
cancers. We first performed whole-genome sequencing of two patients with triple-negative, 
basal-like breast cancer with a primary, 4 and 5 matched metastases, and a matched normal 
tissue to define the germline genotype. We then defined clones by SciClone (Miller et al., 2014), 
demonstrating that multiple clones are present in the primary and leave to metastasize. 
Additionally, these metastases are made up of more than one clone in every instance. This is in 
contrast to previous research mostly from other cancer types where monoclonal seeding 
appears to predominate. We then expand these findings in Chapter 2 in 16 patients, 
demonstrating both monoclonal seeding and polyclonal seeding. Both basal-like and luminal 
breast cancers demonstrate each model of seeding. 
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Previous literature suggests a single cell escapes the primary and then diversifies during 
metastasis. A seminal paper using DNA sequencing of a matched tumor and metastasis was in 
renal cell carcinoma, demonstrating branched evolution with a single cell of origin seeding 
distant metastasis (Gerlinger et al., 2012). A study of basal-like breast cancer, the matched 
metastasis, and a xenograft show high percentage of shared genetics across all 3 tumors 
(Krøigård et al., 2015). Single cell sequencing of one breast cancer with one matched liver 
metastasis suggest a single cell seeded the distant site (Navin et al., 2011). This is corroborated 
by a large panel of matched primary and brain metastases sequenced, showing continued 
evolution and acquisition of resistance mechanisms in the brain metastasis specifically 
(Brastianos et al., 2015). A larger study in prostate cancer suggests metastasis can seed other 
metastases (Gundem et al., 2015). Other studies in non-small cell lung cancer (Govindan et al., 
2012), colorectal cancer, and ovarian cancer (Castellarin et al., 2013; Schwarz et al., 2015) all 
shed light on the cancer evolution through metastasis.  
Recent in vivo evidence, however, sheds light on how polyclonal seeding might be 
possible. First in a genetically engineered pancreatic cancer mouse model, metastasis was 
shown to be a result from at least two distinct populations (Maddipati and Stanger, 2015). 
Recent evidence using a breast cancer genetically engineered mouse model further 
demonstrates not only polyclonal seeding of lung metastases but also that tumors cells self-
seed the contralateral fat pad of the mouse (Cheung et al., 2016). Furthermore, recent 
investigation demonstrates the fluid dynamics and video imaging of how exactly polyclonal 
seeding could occur (Au et al., 2016).  
Why would polyclonal seeding occur in metastasis? What is the evolutionary advantage? 
In order for a breast cancer to break off, survive through circulation, successfully land in a 
distant organ, and survive all while escaping immune surveillance, some level of genetic 
diversity and adaptation is needed. Others have observed clumps of circulating tumor cells in 
cancer patients (Aceto et al., 2014), further suggesting that multiple cells are needed in order for 
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metastasis to be successful. Potentially, this genetic diversity would be better shared across 
multiple tumor cells rather than the entire genetic burden existing in one cell. Furthermore, 
cross-talk between multiple types of cells could be beneficial: studies in our lab have 
demonstrated that most basal-like cancers show a mixed population of tumor cells containing 
both claudin-low (stem-cell like population) and basal-like cells, when we isolate only 1 
population of cells, the cells can repopulate both populations such that both populations are in 
the final culture (Prat et al., 2010). In addition, Zhang et al (Zhang et al., 2015) showed there is 
growth factor cross talk between these two populations, such that one makes the ligand the 
other the receptor; thus both populations would be needed in order to keep a tumor going. This 
suggests both tumor cell plasticity as well as a need for both populations to exist for the cancer 
cells to continue to grow. 
 
Similarity of Primary and Metastatic Breast Cancer 
When we looked at the RNA expression profiles of our 86 tumors compared to over 
1000 breast cancers from TCGA, the metastases were more similar to the matching primary 
tumor than other breast cancers. This confirms previous findings from our group with a smaller 
number of metastases and primaries (Harrell et al., 2012). Additionally, the primary breast 
cancer carries significant prognostic information including future site of first metastasis and 
overall survival. All of these conclusions provide evidence for much of the metastatic phenotype 
residing within the original primary breast cancer. Identifying these genetic features could 
provide therapeutic targets in the neo-adjuvant and adjuvant settings to ultimately prevent 
metastatic spread if these critical factors are identified. 
Recent publications have identified that a majority of the ‘genetic drivers’ are private to 
distant brain metastasis, not established in the original primary (Brastianos et al., 2015). While 
investigating our DNA sequencing data, we observed that mutations called in one or two tumors 
were present at very low coverage in the other tumors from that patient, especially in the 
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primary breast cancer. We computationally re-interrogated these mutations in two ways: first, 
we took the union set of mutations from one patient and counted the mutant allelic reads in each 
tumor. Second, we took all sequencing runs from a single patient, collapsed them into one 
“tumor” and de novo called mutations. We confirmed all of the mutations that had been 
identified from each tumor individually compared to the normal, only missing some 
insertions/deletions (which are notoriously difficult to identify). In the whole genome sequencing 
paper, we identify 2-3% clones in Patient A1 in the primary breast cancer specific to the liver 
and adrenal metastasis, proving that the original breast cancer contains multiple clones that 
together seed distant metastasis. These were only identified through computational re-
interrogation. In Chapter 2, we formally examine this re-interrogation and demonstrate a 30% 
increase in ‘founder’ mutations across the dataset that would have been otherwise missed.  
It is absolutely critical for evolutionary metastatic studies to perform computational re-
interrogation. In order to understand the timing with which drives are acquired, we must first 
accurately identify when in that patient’s cancer the genetic alteration occurred. Improper 
conclusions will be drawn if a depth coverage is required upon re-interrogation. Multi-regional 
sequencing of primary breast cancers demonstrated that primary breast cancers can have >10 
clones in them at times. Thus, a clone that seeds a metastasis and has 20-40% variant allele 
frequency in the metastasis could be as low as 1-2% in the primary when performing bulk 
sequencing of the primary. If we require a variant frequency cutoff of 5%, these would be 
missed. Re-analysis of publicly available metastatic datasets will be needed in the future to fully 
appreciate how different the conclusions could be in an independent dataset. 
 
Timing of Copy Number and Point Mutation Alterations in Cancer Development 
Recent literature described the timing of acquired genetic alteration. The authors 
showed that mutations are acquired in a linear function of time such that the older the tumors, 
the more mutations that tumor would have. This fits with other publications that demonstrate 
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pediatric cancers have relatively simple genetics – maybe one or two mutations – compared to 
melanoma or lung cancer, which tend to have the highest mutation burden caused by DNA 
mutation inducing origins (i.e. smoking and UV light). In contrast, the authors demonstrate that 
copy number events occur in large smatterings wherein the genome is significantly disrupted in 
one point in time, followed by large changes, and then relative stability. This difference in the 
process of acquiring genetic alterations fits with our findings: there seems to be a relative steady 
increase in the number of mutations as these clonal populations grow in the primary, 
metastasize, and seed distant sites. In contrast, when copy number alterations occur, it seems 
as though huge amounts of the genome are altered all at once. There is relatively little ‘private’ 
copy number alteration in the genomes of our metastatic patients.  
 Copy number alterations as a mechanism driving breast cancer progression is incredibly 
important. Copy number changes alter a large number of genes effectively in comparison to 
mutations. Thus, the cancer has a mechanism for generating large genetic diversity quickly. In 
our metastatic breast cancer patients as well as in primary breast cancer, copy number was the 
dominant mechanism for causing drivers. In trying to identify common mechanisms of 
metastasis, only one mutation was shared among our two patients with whole genome 
sequencing data and among 13/16 patients with whole exome sequencing (i.e. TP53). In 
contrast, 15/16 patients had common copy number altered regions, and these alterations were 
almost always established in the primary and maintained throughout metastasis. 
 The only common mutation across both our two patients with whole genome sequencing 
and in the whole exome dataset was TP53. TP53 is the most highly mutated gene in cancer and 
is known to be negatively prognostic in breast cancer. Interestingly, the basal-like breast cancer 
patients in our dataset were more likely to have missense mutations, and when these missense 
mutations occurred, they were also expressed in the RNA. In contrast, the luminal metastatic 
patients often had complete frame-shift, insertions/deletions, or early stop-codon mutations. 
These alterations were not expressed in the RNA, as they likely produced nonsensical RNA 
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transcripts which would be degraded by nonsense mediated decay. Finally, these alterations 
were all established in the original primary and carried in every single metastasis in every 
patient in which the TP53 alteration was present. This provides definitive evidence that TP53 
disruption is a critical event to generate breast cancer metastasis regardless of subtype. 
Aggressive breast cancer is a heavily copy-number altered disease. Triple negative 
breast cancers of the basal-like molecular subtype have the worst 5-year overall survival and 
the largest burden of copy number alterations. Studying only the ER+, luminal breast cancers, 
the poorest prognostic breast cancers again have TP53 alteration and significant copy number 
destabilization. Potentially, TP53 disruption is a critical event to generate genomic 
destabilization and ensuing copy number alteration. This also fits with the previous hypothesis 
that copy number alterations occur in bursts. Finally, this is consistent with one previous study 
which demonstrate that TP53 disruption and copy number alteration are the only occurrences 
shared in pre-invasive ductal carcinoma in situ, invasive breast cancer, and a matched lymph 
node. 
 
Heterogeneity of Primary Breast Cancer Genetic Drivers 
Previous work in our group as well as many others have demonstrated the large amount 
of variation in primary breast cancer. Even within the PAM50 molecular subtypes or clinical 
subtypes of hormone receptor positive versus hormone receptor negative disease, there are 
large variations in clinical response and survival. In Chapter 4, we strove to identify variation of 
genetic drivers in primary breast cancer with the similar computational strategy as applied to our 
metastatic tumors. 
 Defining 5 distinct ‘driver’ subtypes of breast cancer, we observed that these divisions 
were not based on estrogen receptor positivity. In contrast, we had two subgroups with mixed 
HER2 positive, ER positive, and ER negative breast cancers. When stratifying by ER positivity, 
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there was still significant survival differences across our ‘driver’ subgroups. This demonstrates 
that there are common mechanisms driving breast cancer across the different subgroups. 
 Interestingly, our most mixed subgroup of cancer had the worst overall survival but an 
elevated immune infiltrate. Immune infiltrate typically predicts an improved prognosis in both 
HER2-enriched and basal-like molecular subtypes but not the luminal subtypes. These immune 
infiltrated PAM50 Luminal B tumors that end up in the mixed driver subtype have a poor 
prognosis. They also demonstrate a loss of estrogen regulation and loss of the mature luminal 
phenotype. Whether this is due to the increased immune infiltration thus decreasing the 
differentiation or an actual biologic down-regulation of estrogen receptor is unknown; however, 
previous research in the fields of both oncology and rheumatology have demonstrated 
estrogen’s immune repressive affects. The possibility that estrogen may mediate the 
ineffectiveness of immune infiltrate has very interesting therapeutic implications. In metastasis, 
often estrogen receptor-positive primaries lose estrogen signaling and become more 
dedifferentiated. Potentially, in the metastatic setting, immune modulatory-therapies could be 
harnessed with more power than in the adjuvant setting when ER-positive tumors are highly 
estrogen dependent. Further investigation is needed to test this hypothesis directly in an in vivo 
and in vitro setting. 
 
Clinical Implications of Our Research Findings 
Our findings of the relationship between primaries and metastases has significant clinical 
implications. First, if polyclonal seeding is indeed common in triple negative breast cancer 
metastases, then therapeutics targeting multiple clones will be needed to effectively eradicate 
these subclones. This supports previous evidence of why single targeted therapies sometimes 
do not work in breast cancer due to resistance mechanisms: a primary breast cancer as multiple 
subclonal populations residing within the tumor that together mediate metastasis. Thus, an 
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understanding of the heterogeneity existing in a primary breast cancer is critical for effective 
halting of metastatic progression. 
While dual targeted therapy is necessary to block metastatic progression, it is also 
encouraging that much of the metastatic potential resides within the original tumor. We 
demonstrate that a majority of the copy number alterations occur in both the primary tumor and 
the matched metastases. In addition, when filtering the mutations (which are likely acquired as a 
linear progression of time) to those that significantly alter the gene expression network and thus 
are called ‘drivers’, a significant majority of them are established in the primary breast cancer. 
Therefore, it is possible that therapies targeting this original population that has metastatic 
potential could be delivered effectively in the adjuvant setting thus preventing metastatic spread. 
Alternatively, if metastasis does occur prior to detection, potentially effective targeting of these 
‘founder’ mutations that are present both in the primary breast cancer and in the metastasis 
could prevent and treat future sites of metastasis. 
Future research targeting copy number alterations is desperately needed. It has long 
been known that a majority of driver alterations are a result of copy number alteration. 1q 
amplification, 5q amplification, 8p loss, and 8q amplification are recurrent copy number 
alterations across all of breast cancer and are not subtype specific. In addition, triple negative 
breast cancer have subtype specific copy number alterations known to drive the tumor 
phenotype and are conserved across species. In our study as well as previous research have 
demonstrated that copy number alteration is an extremely early event, present in pre-invasive 
ductal carcinoma in situ, and are maintained not only in primary breast cancer but also distant 
metastasis. Therefore, it should not be ignored as a therapeutic target. Clearly, copy number 
alteration is a fundamental mechanism of oncogenic activity in breast cancer. Our research in 
Chapters 1 and 2 support that copy number alteration is a shared mechanism across 
metastasis. Furthermore, in Chapter 3, we demonstrate that copy number alteration causes 
more drivers that can separate subtypes of breast cancer than mutation. Finally, it is generally 
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accepted in the field that copy number alteration is a much more effective mechanism of 
genomic alteration than mutation, as whole arm amplifications can amplify a host of oncogenic 
factors at once. Further research in targeting these copy number alterations is desperately 
needed, especially in hormone receptor negative breast cancer. 
Conclusions 
 In summary, our research has demonstrated that both polyclonal and monoclonal 
seeding can occur and both are common mechanisms of metastasis across both hormone 
receptor positive and negative breast cancers, that most genetic drivers are established in the 
original breast cancer, and that common mechanisms exist across the molecular subtypes of 
breast cancer. We hope to continue investigating the >50 women’s metastases that have 
graciously donated their bodies to medical research at the end of their lives to continue to 
enhance our understanding of clonality, evolution, and genetic drivers of metastasis. We 
furthermore envision a day in which the proper combinatorial therapies that target TP53 as well 
as copy number amplifications can effectively prevent and treat metastatic progression in breast 
cancer. We firmly believe that continue research in metastatic breast cancer is needed to fully 
understand the molecular mechanisms of therapeutic resistance, site-specific metastasis, and 
therapeutic targets in the advanced setting. Only then can we begin to develop the proper 
therapeutic approaches to ultimately help our patients live longer, healthier lives.  
  
 
 
119 
REFERENCES 
Aceto, N., Bardia, A., Miyamoto, D.T., Donaldson, M.C., Wittner, B.S., Spencer, J.A., Yu, M., 
Pely, A., Engstrom, A., Zhu, H., et al. (2014). Circulating tumor cell clusters are oligoclonal 
precursors of breast cancer metastasis. Cell 158, 1110–1122. 
Anders, C., and Carey, L.A. (2008). Understanding and treating triple-negative breast cancer. 
Oncol. Williston Park 22, 1233–1239; discussion 1239–1240, 1243. 
André, F., Bachelot, T., Campone, M., Dalenc, F., Perez-Garcia, J.M., Hurvitz, S.A., Turner, N., 
Rugo, H., Smith, J.W., Deudon, S., et al. (2013). Targeting FGFR with dovitinib (TKI258): 
preclinical and clinical data in breast cancer. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 
19, 3693–3702. 
Au, S.H., Storey, B.D., Moore, J.C., Tang, Q., Chen, Y.-L., Javaid, S., Sarioglu, A.F., Sullivan, 
R., Madden, M.W., O’Keefe, R., et al. (2016). Clusters of circulating tumor cells traverse 
capillary-sized vessels. Proc. Natl. Acad. Sci. U. S. A. 113, 4947–4952. 
Bertucci, F., Finetti, P., Guille, A., Adélaïde, J., Garnier, S., Carbuccia, N., Monneur, A., 
Charafe-Jauffret, E., Goncalves, A., Viens, P., et al. (2014). Comparative genomic analysis of 
primary tumors and metastases in breast cancer. Oncotarget. 
Bertucci, F., Finetti, P., Guille, A., Adélaïde, J., Garnier, S., Carbuccia, N., Monneur, A., 
Charafe-Jauffret, E., Goncalves, A., Viens, P., et al. (2016). Comparative genomic analysis of 
primary tumors and metastases in breast cancer. Oncotarget. 
Bindea, G., Mlecnik, B., Tosolini, M., Kirilovsky, A., Waldner, M., Obenauf, A.C., Angell, H., 
Fredriksen, T., Lafontaine, L., Berger, A., et al. (2013). Spatiotemporal dynamics of intratumoral 
immune cells reveal the immune landscape in human cancer. Immunity 39, 782–795. 
Bos, P.D., Zhang, X.H., Nadal, C., Shu, W., Gomis, R.R., Nguyen, D.X., Minn, A.J., van de 
Vijver, M.J., Gerald, W.L., Foekens, J.A., et al. (2009). Genes that mediate breast cancer 
metastasis to the brain. Nature 459, 1005–1009. 
Bouaoun, L., Sonkin, D., Ardin, M., Hollstein, M., Zavadil, J., and Olivier, M. (2016). TP53 
Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics 
Data. Hum. Mutat. 37, 865–876. 
Brastianos, P.K., Carter, S.L., Santagata, S., Cahill, D.P., Taylor-Weiner, A., Jones, R.T., Van 
Allen, E.M., Lawrence, M.S., Horowitz, P.M., Cibulskis, K., et al. (2015). Genomic 
Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic 
Targets. Cancer Discov. 5, 1164–1177. 
de Bruin, E.C., McGranahan, N., Mitter, R., Salm, M., Wedge, D.C., Yates, L., Jamal-Hanjani, 
M., Shafi, S., Murugaesu, N., Rowan, A.J., et al. (2014). Spatial and temporal diversity in 
genomic instability processes defines lung cancer evolution. Science 346, 251–256. 
Butler, T.M., Johnson-Camacho, K., Peto, M., Wang, N.J., Macey, T.A., Korkola, J.E., Koppie, 
T.M., Corless, C.L., Gray, J.W., and Spellman, P.T. (2015). Exome Sequencing of Cell-Free 
 
 
120 
DNA from Metastatic Cancer Patients Identifies Clinically Actionable Mutations Distinct from 
Primary Disease. PloS One 10, e0136407. 
Camp, J.T., Elloumi, F., Roman-Perez, E., Rein, J., Stewart, D.A., Harrell, J.C., Perou, C.M., 
and Troester, M.A. (2011). Interactions with fibroblasts are distinct in Basal-like and luminal 
breast cancers. Mol. Cancer Res. MCR 9, 3–13. 
Campbell, P.J., Pleasance, E.D., Stephens, P.J., Dicks, E., Rance, R., Goodhead, I., Follows, 
G.A., Green, A.R., Futreal, P.A., and Stratton, M.R. (2008). Subclonal phylogenetic structures in 
cancer revealed by ultra-deep sequencing. Proc. Natl. Acad. Sci. U. S. A. 105, 13081–13086. 
Cancer Genome Atlas, N. (2012). Comprehensive molecular portraits of human breast tumours. 
Nature 490, 61–70. 
Cardoso, F., van’t Veer, L.J., Bogaerts, J., Slaets, L., Viale, G., Delaloge, S., Pierga, J.-Y., 
Brain, E., Causeret, S., DeLorenzi, M., et al. (2016). 70-Gene Signature as an Aid to Treatment 
Decisions in Early-Stage Breast Cancer. N. Engl. J. Med. 375, 717–729. 
Carey, L.A., Perou, C.M., Livasy, C.A., Dressler, L.G., Cowan, D., Conway, K., Karaca, G., 
Troester, M.A., Tse, C.K., Edmiston, S., et al. (2006). Race, breast cancer subtypes, and 
survival in the Carolina Breast Cancer Study. JAMA 295, 2492–2502. 
Castellarin, M., Milne, K., Zeng, T., Tse, K., Mayo, M., Zhao, Y., Webb, J.R., Watson, P.H., 
Nelson, B.H., and Holt, R.A. (2013). Clonal evolution of high-grade serous ovarian carcinoma 
from primary to recurrent disease. J. Pathol. 229, 515–524. 
Cerami, E., Gao, J., Dogrusoz, U., Gross, B.E., Sumer, S.O., Aksoy, B.A., Jacobsen, A., Byrne, 
C.J., Heuer, M.L., Larsson, E., et al. (2012). The cBio cancer genomics portal: an open platform 
for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401–404. 
Chen, K., Wallis, J.W., McLellan, M.D., Larson, D.E., Kalicki, J.M., Pohl, C.S., McGrath, S.D., 
Wendl, M.C., Zhang, Q., Locke, D.P., et al. (2009). BreakDancer: an algorithm for high-
resolution mapping of genomic structural variation. Nat. Methods 6, 677–681. 
Chen, K., Chen, L., Fan, X., Wallis, J., Ding, L., and Weinstock, G. (2014). TIGRA: a targeted 
iterative graph routing assembler for breakpoint assembly. Genome Res. 24, 310–317. 
Cheung, K.J., Padmanaban, V., Silvestri, V., Schipper, K., Cohen, J.D., Fairchild, A.N., Gorin, 
M.A., Verdone, J.E., Pienta, K.J., Bader, J.S., et al. (2016). Polyclonal breast cancer 
metastases arise from collective dissemination of keratin 14-expressing tumor cell clusters. 
Proc. Natl. Acad. Sci. U. S. A. 113, E854–E863. 
Ciriello, G., Cerami, E., Sander, C., and Schultz, N. (2012). Mutual exclusivity analysis identifies 
oncogenic network modules. Genome Res. 22, 398–406. 
Ciriello, G., Sinha, R., Hoadley, K.A., Jacobsen, A.S., Reva, B., Perou, C.M., Sander, C., and 
Schultz, N. (2013). The molecular diversity of Luminal A breast tumors. Breast Cancer Res. 
Treat. 141, 409–420. 
 
 
121 
Ciriello, G., Gatza, M.L., Beck, A.H., Wilkerson, M.D., Rhie, S.K., Pastore, A., Zhang, H., 
McLellan, M., Yau, C., Kandoth, C., et al. (2015). Comprehensive Molecular Portraits of Invasive 
Lobular Breast Cancer. Cell 163, 506–519. 
Cummings, M.C., Simpson, P.T., Reid, L.E., Jayanthan, J., Skerman, J., Song, S., McCart 
Reed, A.E., Kutasovic, J.R., Morey, A.L., Marquart, L., et al. (2014). Metastatic progression of 
breast cancer: insights from 50 years of autopsies. J. Pathol. 232, 23–31. 
Curtis, C., Shah, S.P., Chin, S.-F., Turashvili, G., Rueda, O.M., Dunning, M.J., Speed, D., 
Lynch, A.G., Samarajiwa, S., Yuan, Y., et al. (2012). The genomic and transcriptomic 
architecture of 2,000 breast tumours reveals novel subgroups. Nature 486, 346–352. 
Dabney, A.R. (2006). ClaNC: point-and-click software for classifying microarrays to nearest 
centroids. Bioinforma. Oxf. Engl. 22, 122–123. 
Daud, A.I., Loo, K., Pauli, M.L., Sanchez-Rodriguez, R., Sandoval, P.M., Taravati, K., Tsai, K., 
Nosrati, A., Nardo, L., Alvarado, M.D., et al. (2016). Tumor immune profiling predicts response 
to anti–PD-1 therapy in human melanoma. J. Clin. Invest. 126, 3447–3452. 
Dees, E.C., Cohen, R.B., von Mehren, M., Stinchcombe, T.E., Liu, H., Venkatakrishnan, K., 
Manfredi, M., Fingert, H., Burris, H.A., 3rd, and Infante, J.R. (2012a). Phase I study of aurora A 
kinase inhibitor MLN8237 in advanced solid tumors: safety, pharmacokinetics, 
pharmacodynamics, and bioavailability of two oral formulations. Clin Cancer Res 18, 4775–
4784. 
Dees, N.D., Zhang, Q., Kandoth, C., Wendl, M.C., Schierding, W., Koboldt, D.C., Mooney, T.B., 
Callaway, M.B., Dooling, D., Mardis, E.R., et al. (2012b). MuSiC: identifying mutational 
significance in cancer genomes. Genome Res. 22, 1589–1598. 
DePristo, M.A., Banks, E., Poplin, R., Garimella, K.V., Maguire, J.R., Hartl, C., Philippakis, A.A., 
del Angel, G., Rivas, M.A., Hanna, M., et al. (2011). A framework for variation discovery and 
genotyping using next-generation DNA sequencing data. Nat. Genet. 43, 491–498. 
Ding, L., Ellis, M.J., Li, S., Larson, D.E., Chen, K., Wallis, J.W., Harris, C.C., McLellan, M.D., 
Fulton, R.S., Fulton, L.L., et al. (2010). Genome remodelling in a basal-like breast cancer 
metastasis and xenograft. Nature 464, 999–1005. 
Ding, L., Ley, T.J., Larson, D.E., Miller, C.A., Koboldt, D.C., Welch, J.S., Ritchey, J.K., Young, 
M.A., Lamprecht, T., McLellan, M.D., et al. (2012). Clonal evolution in relapsed acute myeloid 
leukaemia revealed by whole-genome sequencing. Nature 481, 506–510. 
Ellis, M.J., Ding, L., Shen, D., Luo, J., Suman, V.J., Wallis, J.W., Van Tine, B.A., Hoog, J., 
Goiffon, R.J., Goldstein, T.C., et al. (2012). Whole-genome analysis informs breast cancer 
response to aromatase inhibition. Nature 486, 353–360. 
Fan, C., Prat, A., Parker, J.S., Liu, Y., Carey, L.A., Troester, M.A., and Perou, C.M. (2011). 
Building prognostic models for breast cancer patients using clinical variables and hundreds of 
gene expression signatures. BMC Med. Genomics 4, 3. 
Fidler, I.J. (2001). Seed and soil revisited: contribution of the organ microenvironment to cancer 
metastasis. Surg Oncol Clin N Am 10, 257–269, vii – viiii. 
 
 
122 
Forbes, S.A., Beare, D., Gunasekaran, P., Leung, K., Bindal, N., Boutselakis, H., Ding, M., 
Bamford, S., Cole, C., Ward, S., et al. (2015). COSMIC: exploring the world’s knowledge of 
somatic mutations in human cancer. Nucleic Acids Res. 43, D805–D811. 
Gao, J., Aksoy, B.A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S.O., Sun, Y., Jacobsen, 
A., Sinha, R., Larsson, E., et al. (2013). Integrative analysis of complex cancer genomics and 
clinical profiles using the cBioPortal. Sci. Signal. 6, pl1. 
Gatza, M.L., Lucas, J.E., Barry, W.T., Kim, J.W., Wang, Q., Crawford, M.D., Datto, M.B., Kelley, 
M., Mathey-Prevot, B., Potti, A., et al. (2010). A pathway-based classification of human breast 
cancer. Proc. Natl. Acad. Sci. U. S. A. 107, 6994–6999. 
Gatza, M.L., Silva, G.O., Parker, J.S., Fan, C., and Perou, C.M. (2014). An integrated genomics 
approach identifies drivers of proliferation in luminal-subtype human breast cancer. Nat. Genet. 
46, 1051–1059. 
Gerlinger, M., Rowan, A.J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., 
Matthews, N., Stewart, A., Tarpey, P., et al. (2012). Intratumor heterogeneity and branched 
evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883–892. 
Gewinner, C., Wang, Z.C., Richardson, A., Teruya-Feldstein, J., Etemadmoghadam, D., 
Bowtell, D., Barretina, J., Lin, W.M., Rameh, L., Salmena, L., et al. (2009). Evidence that inositol 
polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. Cancer 
Cell 16, 115–125. 
Glas, A.M., Floore, A., Delahaye, L.J.M.J., Witteveen, A.T., Pover, R.C.F., Bakx, N., Lahti-
Domenici, J.S.T., Bruinsma, T.J., Warmoes, M.O., Bernards, R., et al. (2006). Converting a 
breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics 7, 
278. 
Govindan, R., Ding, L., Griffith, M., Subramanian, J., Dees, N.D., Kanchi, K.L., Maher, C.A., 
Fulton, R., Fulton, L., Wallis, J., et al. (2012). Genomic landscape of non-small cell lung cancer 
in smokers and never-smokers. Cell 150, 1121–1134. 
Gril, B., Palmieri, D., Qian, Y., Anwar, T., Liewehr, D.J., Steinberg, S.M., Andreu, Z., Masana, 
D., Fernandez, P., Steeg, P.S., et al. (2013). Pazopanib inhibits the activation of PDGFRbeta-
expressing astrocytes in the brain metastatic microenvironment of breast cancer cells. Am J 
Pathol 182, 2368–2379. 
Gundem, G., Van Loo, P., Kremeyer, B., Alexandrov, L.B., Tubio, J.M.C., Papaemmanuil, E., 
Brewer, D.S., Kallio, H.M.L., Högnäs, G., Annala, M., et al. (2015). The evolutionary history of 
lethal metastatic prostate cancer. Nature 520, 353–357. 
Haque, R., Ahmed, S.A., Inzhakova, G., Shi, J., Avila, C., Polikoff, J., Bernstein, L., Enger, S.M., 
and Press, M.F. (2012). Impact of Breast Cancer Subtypes and Treatment on Survival: An 
Analysis Spanning Two Decades. Cancer Epidemiol. Biomarkers Prev. 21, 1848–1855. 
Harrell, J.C., Prat, A., Parker, J.S., Fan, C., He, X., Carey, L., Anders, C., Ewend, M., and 
Perou, C.M. (2012). Genomic analysis identifies unique signatures predictive of brain, lung, and 
liver relapse. Breast Cancer Res Treat 132, 523–535. 
 
 
123 
Hoadley, K.A., Weigman, V.J., Fan, C., Sawyer, L.R., He, X., Troester, M.A., Sartor, C.I., 
Rieger-House, T., Bernard, P.S., Carey, L.A., et al. (2007). EGFR associated expression 
profiles vary with breast tumor subtype. BMC Genomics 8, 258. 
Hoadley, K.A., Siegel, M.B., Kanchi, K.L., Miller, C.A., Ding, L., Zhao, W., He, X., Parker, J.S., 
Wendl, M.C., Fulton, R.S., et al. (2016). Tumor evolution in two patients with basal-like breast 
cancer a retrospective genomics study of multiple metastases. PLOS Med. 
Hoon, M.J.L. de, Imoto, S., Nolan, J., and Miyano, S. (2004). Open source clustering software. 
Bioinformatics 20, 1453–1454. 
Hou, J.P., and Ma, J. (2014). DawnRank: discovering personalized driver genes in cancer. 
Genome Med. 6, 56. 
Hu, Z., Fan, C., Livasy, C., He, X., Oh, D.S., Ewend, M.G., Carey, L.A., Subramanian, S., West, 
R., Ikpatt, F., et al. (2009). A compact VEGF signature associated with distant metastases and 
poor outcomes. BMC Med. 7, 9. 
Huang, H., Liu, Y., Yuan, M., and Marron, J.S. (2015). Statistical Significance of Clustering 
using Soft Thresholding. J. Comput. Graph. Stat. Jt. Publ. Am. Stat. Assoc. Inst. Math. Stat. 
Interface Found. N. Am. 24, 975–993. 
Iglesia, M.D., Vincent, B.G., Parker, J.S., Hoadley, K.A., Carey, L.A., Perou, C.M., and Serody, 
J.S. (2014). Prognostic B-cell signatures using mRNA-seq in patients with subtype-specific 
breast and ovarian cancer. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 20, 3818–3829. 
Ip, L.R.H., Poulogiannis, G., Viciano, F.C., Sasaki, J., Kofuji, S., Spanswick, V.J., Hochhauser, 
D., Hartley, J.A., Sasaki, T., and Gewinner, C.A. (2015). Loss of INPP4B causes a DNA repair 
defect through loss of BRCA1, ATM and ATR and can be targeted with PARP inhibitor 
treatment. Oncotarget 6, 10548–10562. 
Josephidou, M., Lynch, A.G., and Tavaré, S. (2015). multiSNV: a probabilistic approach for 
improving detection of somatic point mutations from multiple related tumour samples. Nucleic 
Acids Res. 43, e61. 
Juric, D., Castel, P., Griffith, M., Griffith, O.L., Won, H.H., Ellis, H., Ebbesen, S.H., Ainscough, 
B.J., Ramu, A., Iyer, G., et al. (2015). Convergent loss of PTEN leads to clinical resistance to a 
PI(3)Kα inhibitor. Nature 518, 240–244. 
Kanehisa, M., Goto, S., Sato, Y., Furumichi, M., and Tanabe, M. (2012). KEGG for integration 
and interpretation of large-scale molecular data sets. Nucleic Acids Res. 40, D109–D114. 
Kardos, J., Chai, S., Mose, L.E., Selitsky, S.R., Krishnan, B., Saito, R., Iglesia, M.D., Milowsky, 
M.I., Parker, J.S., Kim, W.Y., et al. (2016). Claudin-low bladder tumors are immune infiltrated 
and actively immune suppressed. JCI Insight 1. 
Koboldt, D.C., Zhang, Q., Larson, D.E., Shen, D., McLellan, M.D., Lin, L., Miller, C.A., Mardis, 
E.R., Ding, L., and Wilson, R.K. (2012). VarScan 2: somatic mutation and copy number 
alteration discovery in cancer by exome sequencing. Genome Res. 22, 568–576. 
 
 
124 
Krøigård, A.B., Larsen, M.J., Lænkholm, A.-V., Knoop, A.S., Jensen, J.D., Bak, M., 
Mollenhauer, J., Kruse, T.A., and Thomassen, M. (2015). Clonal expansion and linear genome 
evolution through breast cancer progression from pre-invasive stages to asynchronous 
metastasis. Oncotarget 6, 5634–5649. 
Landrum, M.J., Lee, J.M., Riley, G.R., Jang, W., Rubinstein, W.S., Church, D.M., and Maglott, 
D.R. (2014). ClinVar: public archive of relationships among sequence variation and human 
phenotype. Nucleic Acids Res. 42, D980–D985. 
Larson, D.E., Harris, C.C., Chen, K., Koboldt, D.C., Abbott, T.E., Dooling, D.J., Ley, T.J., 
Mardis, E.R., Wilson, R.K., and Ding, L. (2012). SomaticSniper: identification of somatic point 
mutations in whole genome sequencing data. Bioinforma. Oxf. Engl. 28, 311–317. 
Larson, D.E., Abbott, T.E., and Wilson, R.K. (2014). Using SomaticSniper to Detect Somatic 
Single Nucleotide Variants. Curr. Protoc. Bioinforma. Ed. Board Andreas Baxevanis Al 15, 
15.5.1–15.5.8. 
Lawrence, M.S., Stojanov, P., Polak, P., Kryukov, G.V., Cibulskis, K., Sivachenko, A., Carter, 
S.L., Stewart, C., Mermel, C.H., Roberts, S.A., et al. (2013). Mutational heterogeneity in cancer 
and the search for new cancer-associated genes. Nature 499, 214–218. 
Ley, T.J., Mardis, E.R., Ding, L., Fulton, B., McLellan, M.D., Chen, K., Dooling, D., Dunford-
Shore, B.H., McGrath, S., Hickenbotham, M., et al. (2008). DNA sequencing of a cytogenetically 
normal acute myeloid leukaemia genome. Nature 456, 66–72. 
Li, B., and Dewey, C.N. (2011). RSEM: accurate transcript quantification from RNA-Seq data 
with or without a reference genome. BMC Bioinformatics 12, 323. 
Li, H., and Durbin, R. (2009). Fast and accurate short read alignment with Burrows-Wheeler 
transform. Bioinforma. Oxf. Engl. 25, 1754–1760. 
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., 
Durbin, R., and 1000 Genome Project Data Processing Subgroup (2009). The Sequence 
Alignment/Map format and SAMtools. Bioinforma. Oxf. Engl. 25, 2078–2079. 
Li, S., Shen, D., Shao, J., Crowder, R., Liu, W., Prat, A., He, X., Liu, S., Hoog, J., Lu, C., et al. 
(2013). Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of 
Breast-Cancer-Derived Xenografts. Cell Rep. 4. 
Lin, N.U., Claus, E., Sohl, J., Razzak, A.R., Arnaout, A., and Winer, E.P. (2008). Sites of distant 
recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high 
incidence of central nervous system metastases. Cancer 113, 2638–2645. 
Maddipati, R., and Stanger, B.Z. (2015). Pancreatic Cancer Metastases Harbor Evidence of 
Polyclonality. Cancer Discov. 5, 1086–1097. 
Malin, D., Strekalova, E., Petrovic, V., Deal, A.M., Al Ahmad, A., Adamo, B., Miller, C.R., 
Ugolkov, A., Livasy, C., Fritchie, K., et al. (2014). alphaB-Crystallin: A Novel Regulator of Breast 
Cancer Metastasis to the Brain. Clin Cancer Res 20, 56–67. 
 
 
125 
Malladi, S., Macalinao, D.G., Jin, X., He, L., Basnet, H., Zou, Y., de Stanchina, E., and 
Massagué, J. (2016). Metastatic Latency and Immune Evasion through Autocrine Inhibition of 
WNT. Cell 165, 45–60. 
Mardis, E.R., Ding, L., Dooling, D.J., Larson, D.E., McLellan, M.D., Chen, K., Koboldt, D.C., 
Fulton, R.S., Delehaunty, K.D., McGrath, S.D., et al. (2009). Recurring mutations found by 
sequencing an acute myeloid leukemia genome. N. Engl. J. Med. 361, 1058–1066. 
McCreery, M.Q., Halliwill, K.D., Chin, D., Delrosario, R., Hirst, G., Vuong, P., Jen, K.-Y., 
Hewinson, J., Adams, D.J., and Balmain, A. (2015). Evolution of metastasis revealed by 
mutational landscapes of chemically induced skin cancers. Nat. Med. 21, 1514–1520. 
McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., Garimella, K., 
Altshuler, D., Gabriel, S., Daly, M., et al. (2010). The Genome Analysis Toolkit: a MapReduce 
framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297–1303. 
Meric-Bernstam, F., Frampton, G.M., Ferrer-Lozano, J., Yelensky, R., Pérez-Fidalgo, J.A., 
Wang, Y., Palmer, G.A., Ross, J.S., Miller, V.A., Su, X., et al. (2014). Concordance of genomic 
alterations between primary and recurrent breast cancer. Mol. Cancer Ther. 13, 1382–1389. 
Miller, C.A., White, B.S., Dees, N.D., Griffith, M., Welch, J.S., Griffith, O.L., Vij, R., Tomasson, 
M.H., Graubert, T.A., Walter, M.J., et al. (2014). SciClone: inferring clonal architecture and 
tracking the spatial and temporal patterns of tumor evolution. PLoS Comput. Biol. 10, e1003665. 
Miller, C.A., Gindin, Y., Lu, C., Griffith, O.L., Griffith, M., Shen, D., Hoog, J., Li, T., Larson, D.E., 
Watson, M., et al. (2016). Aromatase inhibition remodels the clonal architecture of estrogen-
receptor-positive breast cancers. Nat. Commun. 7, 12498. 
Minn, A.J., Gupta, G.P., Siegel, P.M., Bos, P.D., Shu, W., Giri, D.D., Viale, A., Olshen, A.B., 
Gerald, W.L., and Massague, J. (2005). Genes that mediate breast cancer metastasis to lung. 
Nature 436, 518–524. 
Moelans, C.B., van der Groep, P., Hoefnagel, L.D.C., van de Vijver, M.J., Wesseling, P., 
Wesseling, J., van der Wall, E., and van Diest, P.J. (2014). Genomic evolution from primary 
breast carcinoma to distant metastasis: Few copy number changes of breast cancer related 
genes. Cancer Lett. 344, 138–146. 
Mose, L.E., Wilkerson, M.D., Hayes, D.N., Perou, C.M., and Parker, J.S. (2014). ABRA: 
improved coding indel detection via assembly-based realignment. Bioinforma. Oxf. Engl. 30, 
2813–2815. 
Mose, L.E., Selitsky, S.R., Bixby, L.M., Marron, D.L., Iglesia, M.D., Serody, J.S., Perou, C.M., 
Vincent, B.G., and Parker, J.S. (2016). Assembly-based inference of B-cell receptor repertoires 
from short read RNA sequencing data with V’DJer. Bioinforma. Oxf. Engl. 
Murtaza, M., Dawson, S.-J., Pogrebniak, K., Rueda, O.M., Provenzano, E., Grant, J., Chin, S.-
F., Tsui, D.W.Y., Marass, F., Gale, D., et al. (2015). Multifocal clonal evolution characterized 
using circulating tumour DNA in a case of metastatic breast cancer. Nat. Commun. 6, 8760. 
 
 
126 
Natesh, K., Bhosale, D., Desai, A., Chandrika, G., Pujari, R., Jagtap, J., Chugh, A., Ranade, D., 
and Shastry, P. (2015). Oncostatin-M differentially regulates mesenchymal and proneural 
signature genes in gliomas via STAT3 signaling. Neoplasia N. Y. N 17, 225–237. 
Navin, N., Kendall, J., Troge, J., Andrews, P., Rodgers, L., McIndoo, J., Cook, K., Stepansky, 
A., Levy, D., Esposito, D., et al. (2011). Tumour evolution inferred by single-cell sequencing. 
Nature 472, 90–94. 
Nazarov, V.I., Pogorelyy, M.V., Komech, E.A., Zvyagin, I.V., Bolotin, D.A., Shugay, M., 
Chudakov, D.M., Lebedev, Y.B., and Mamedov, I.Z. (2015). tcR: an R package for T cell 
receptor repertoire advanced data analysis. BMC Bioinformatics 16, 175. 
Neman, J., Termini, J., Wilczynski, S., Vaidehi, N., Choy, C., Kowolik, C.M., Li, H., Hambrecht, 
A.C., Roberts, E., and Jandial, R. (2014). Human breast cancer metastases to the brain display 
GABAergic properties in the neural niche. Proc Natl Acad Sci U A 111, 984–989. 
Nik-Zainal, S., Davies, H., Staaf, J., Ramakrishna, M., Glodzik, D., Zou, X., Martincorena, I., 
Alexandrov, L.B., Martin, S., Wedge, D.C., et al. (2016). Landscape of somatic mutations in 560 
breast cancer whole-genome sequences. Nature 534, 47–54. 
Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M., Baehner, F.L., Walker, M.G., 
Watson, D., Park, T., et al. (2004). A Multigene Assay to Predict Recurrence of Tamoxifen-
Treated, Node-Negative Breast Cancer. N. Engl. J. Med. 351, 2817–2826. 
Parker, J.S., Mullins, M., Cheang, M.C.U., Leung, S., Voduc, D., Vickery, T., Davies, S., Fauron, 
C., He, X., Hu, Z., et al. (2009). Supervised risk predictor of breast cancer based on intrinsic 
subtypes. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 27, 1160–1167. 
Pereira, B., Chin, S.-F., Rueda, O.M., Vollan, H.-K.M., Provenzano, E., Bardwell, H.A., Pugh, 
M., Jones, L., Russell, R., Sammut, S.-J., et al. (2016). The somatic mutation profiles of 2,433 
breast cancers refine their genomic and transcriptomic landscapes. Nat. Commun. 7, 11479. 
Perou, C.M., Sorlie, T., Eisen, M.B., van de Rijn, M., Jeffrey, S.S., Rees, C.A., Pollack, J.R., 
Ross, D.T., Johnsen, H., Akslen, L.A., et al. (2000). Molecular portraits of human breast 
tumours. Nature 406, 747–752. 
Prat, A., Parker, J.S., Karginova, O., Fan, C., Livasy, C., Herschkowitz, J.I., He, X., and Perou, 
C.M. (2010). Phenotypic and molecular characterization of the claudin-low intrinsic subtype of 
breast cancer. Breast Cancer Res. BCR 12, R68. 
Rebhan, M., Chalifa-Caspi, V., Prilusky, J., and Lancet, D. (1997). GeneCards: integrating 
information about genes, proteins and diseases. Trends Genet. TIG 13, 163. 
Romagnoli, M., Mineva, N.D., Polmear, M., Conrad, C., Srinivasan, S., Loussouarn, D., Barille-
Nion, S., Georgakoudi, I., Dagg, A., McDermott, E.W., et al. (2014). ADAM8 expression in 
invasive breast cancer promotes tumor dissemination and metastasis. EMBO Mol Med 6, 278–
294. 
RStudio Team (2015). RStudio: Integrated Development Environment for R (Boston, MA: 
RStudio, Inc.). 
 
 
127 
Saldanha, A.J. (2004). Java Treeview—extensible visualization of microarray data. 
Bioinformatics 20, 3246–3248. 
Saunders, C.T., Wong, W.S.W., Swamy, S., Becq, J., Murray, L.J., and Cheetham, R.K. (2012). 
Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs. 
Bioinforma. Oxf. Engl. 28, 1811–1817. 
Schroeder, M.P., Rubio-Perez, C., Tamborero, D., Gonzalez-Perez, A., and Lopez-Bigas, N. 
(2014). OncodriveROLE classifies cancer driver genes in loss of function and activating mode of 
action. Bioinforma. Oxf. Engl. 30, i549–i555. 
Schwarz, L.J., Fox, E.M., Balko, J.M., Garrett, J.T., Kuba, M.G., Estrada, M.V., González-
Angulo, A.M., Mills, G.B., Red-Brewer, M., Mayer, I.A., et al. (2014). LYN-activating mutations 
mediate antiestrogen resistance in estrogen receptor-positive breast cancer. J. Clin. Invest. 124, 
5490–5502. 
Schwarz, R.F., Ng, C.K.Y., Cooke, S.L., Newman, S., Temple, J., Piskorz, A.M., Gale, D., 
Sayal, K., Murtaza, M., Baldwin, P.J., et al. (2015). Spatial and Temporal Heterogeneity in High-
Grade Serous Ovarian Cancer: A Phylogenetic Analysis. PLOS Med 12, e1001789. 
Sevenich, L., Bowman, R.L., Mason, S.D., Quail, D.F., Rapaport, F., Elie, B.T., Brogi, E., 
Brastianos, P.K., Hahn, W.C., Holsinger, L.J., et al. (2014). Analysis of tumour- and stroma-
supplied proteolytic networks reveals a brain-metastasis-promoting role for cathepsin S. Nat 
Cell Biol 16, 876–888. 
Shah, S.P., Roth, A., Goya, R., Oloumi, A., Ha, G., Zhao, Y., Turashvili, G., Ding, J., Tse, K., 
Haffari, G., et al. (2012). The clonal and mutational evolution spectrum of primary triple-negative 
breast cancers. Nature 486, 395–399. 
Shain, A.H., Yeh, I., Kovalyshyn, I., Sriharan, A., Talevich, E., Gagnon, A., Dummer, R., North, 
J., Pincus, L., Ruben, B., et al. (2015). The Genetic Evolution of Melanoma from Precursor 
Lesions. N. Engl. J. Med. 373, 1926–1936. 
Sherry, S.T., Ward, M.H., Kholodov, M., Baker, J., Phan, L., Smigielski, E.M., and Sirotkin, K. 
(2001). dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 29, 308–311. 
Shrestha, Y., Schafer, E.J., Boehm, J.S., Thomas, S.R., He, F., Du, J., Wang, S., Barretina, J., 
Weir, B.A., Zhao, J.J., et al. (2012). PAK1 is a breast cancer oncogene that coordinately 
activates MAPK and MET signaling. Oncogene 31, 3397–3408. 
Sihto, H., Lundin, J., Lundin, M., Lehtimäki, T., Ristimäki, A., Holli, K., Sailas, L., Kataja, V., 
Turpeenniemi-Hujanen, T., Isola, J., et al. (2011). Breast cancer biological subtypes and protein 
expression predict for the preferential distant metastasis sites: a nationwide cohort study. Breast 
Cancer Res. BCR 13, R87. 
Silva, G.O., He, X., Parker, J.S., Gatza, M.L., Carey, L.A., Hou, J.P., Moulder, S.L., Marcom, 
P.K., Ma, J., Rosen, J.M., et al. (2015). Cross-species DNA copy number analyses identifies 
multiple 1q21-q23 subtype-specific driver genes for breast cancer. Breast Cancer Res. Treat. 
152, 347–356. 
 
 
128 
Smid, M., Wang, Y., Zhang, Y., Sieuwerts, A.M., Yu, J., Klijn, J.G.M., Foekens, J.A., and 
Martens, J.W.M. (2008). Subtypes of breast cancer show preferential site of relapse. Cancer 
Res. 68, 3108–3114. 
Thorvaldsdóttir, H., Robinson, J.T., and Mesirov, J.P. (2013). Integrative Genomics Viewer 
(IGV): high-performance genomics data visualization and exploration. Brief. Bioinform. 14, 178–
192. 
Tischler, G., and Leonard, S. (2014). biobambam: tools for read pair collation based algorithms 
on BAM files. Source Code Biol. Med. 9, 13. 
Troester, M.A., Lee, M.H., Carter, M., Fan, C., Cowan, D.W., Perez, E.R., Pirone, J.R., Perou, 
C.M., Jerry, D.J., and Schneider, S.S. (2009). Activation of Host Wound Responses in Breast 
Cancer Microenvironment. Clin. Cancer Res. 15, 7020–7028. 
Tusher, V.G., Tibshirani, R., and Chu, G. (2001). Significance analysis of microarrays applied to 
the ionizing radiation response. Proc Natl Acad Sci U A 98, 5116–5121. 
Valiente, M., Obenauf, A.C., Jin, X., Chen, Q., Zhang, X.H., Lee, D.J., Chaft, J.E., Kris, M.G., 
Huse, J.T., Brogi, E., et al. (2014). Serpins promote cancer cell survival and vascular co-option 
in brain metastasis. Cell 156, 1002–1016. 
Wang, K., Singh, D., Zeng, Z., Coleman, S.J., Huang, Y., Savich, G.L., He, X., Mieczkowski, P., 
Grimm, S.A., Perou, C.M., et al. (2010). MapSplice: accurate mapping of RNA-seq reads for 
splice junction discovery. Nucleic Acids Res. 38, e178. 
Wang, L., Cossette, S.M., Rarick, K.R., Gershan, J., Dwinell, M.B., Harder, D.R., and 
Ramchandran, R. (2013). Astrocytes directly influence tumor cell invasion and metastasis in 
vivo. PLoS One 8, e80933. 
Weigelt, B., Glas, A.M., Wessels, L.F.A., Witteveen, A.T., Peterse, J.L., and van’t Veer, L.J. 
(2003). Gene expression profiles of primary breast tumors maintained in distant metastases. 
Proc. Natl. Acad. Sci. U. S. A. 100, 15901–15905. 
Weigman, V.J., Chao, H.-H., Shabalin, A.A., He, X., Parker, J.S., Nordgard, S.H., Grushko, T., 
Huo, D., Nwachukwu, C., Nobel, A., et al. (2012). Basal-like Breast cancer DNA copy number 
losses identify genes involved in genomic instability, response to therapy, and patient survival. 
Breast Cancer Res. Treat. 133, 865–880. 
Wilkerson, M.D., and Hayes, D.N. (2010). ConsensusClusterPlus: a class discovery tool with 
confidence assessments and item tracking. Bioinforma. Oxf. Engl. 26, 1572–1573. 
Wilkerson, M.D., Cabanski, C.R., Sun, W., Hoadley, K.A., Walter, V., Mose, L.E., Troester, 
M.A., Hammerman, P.S., Parker, J.S., Perou, C.M., et al. (2014). Integrated RNA and DNA 
sequencing improves mutation detection in low purity tumors. Nucleic Acids Res. 42, e107. 
Yates, L.R., Gerstung, M., Knappskog, S., Desmedt, C., Gundem, G., Van Loo, P., Aas, T., 
Alexandrov, L.B., Larsimont, D., Davies, H., et al. (2015). Subclonal diversification of primary 
breast cancer revealed by multiregion sequencing. Nat. Med. 21, 751–759. 
 
 
129 
Ye, K., Schulz, M.H., Long, Q., Apweiler, R., and Ning, Z. (2009). Pindel: a pattern growth 
approach to detect break points of large deletions and medium sized insertions from paired-end 
short reads. Bioinforma. Oxf. Engl. 25, 2865–2871. 
Zhang, J., Fujimoto, J., Zhang, J., Wedge, D.C., Song, X., Zhang, J., Seth, S., Chow, C.-W., 
Cao, Y., Gumbs, C., et al. (2014). Intratumor heterogeneity in localized lung adenocarcinomas 
delineated by multiregion sequencing. Science 346, 256–259. 
Zhang, M., Tsimelzon, A., Chang, C.-H., Fan, C., Wolff, A., Perou, C.M., Hilsenbeck, S.G., and 
Rosen, J.M. (2015). Intratumoral Heterogeneity in a Trp53-Null Mouse Model of Human Breast 
Cancer. Cancer Discov. 5, 520–533. 
Zhang, X.H.-F., Wang, Q., Gerald, W., Hudis, C.A., Norton, L., Smid, M., Foekens, J.A., and 
Massagué, J. (2009). Latent bone metastasis in breast cancer tied to Src-dependent survival 
signals. Cancer Cell 16, 67–78. 
Zhao, W., He, X., Hoadley, K.A., Parker, J.S., Hayes, D.N., and Perou, C.M. (2014). 
Comparison of RNA-Seq by poly (A) capture, ribosomal RNA depletion, and DNA microarray for 
expression profiling. BMC Genomics 15, 419. 
 
 
 
